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Friedreich ataxia (FRDA) is a neurodegenerative disease caused by mutations in the frataxin (FXN) gene,
resulting in reduced expression of the mitochondrial protein frataxin. While there currently is no cure for
FRDA, our increasing understanding of the pathophysiology of disease has led to a surge in the development
of potential treatments. As a result, there is a growing need for biological markers of disease progression and
patient response to therapeutic intervention. In this thesis, we developed and validated a lateral flow “dipstick”
immunoassay for the measurement of frataxin protein in multiple peripheral cell types. We measured
significant differences in frataxin levels between controls, carriers, and FRDA patients, and found correlations
between frataxin levels and GAA1 repeat length and age of onset. We then compared the utility of the dipstick assay as a population screening
and diagnostic tool to a separate, Luminex xMAP-based immunoassay, and discuss the advantages and disadvantages of each assay in different clinical settings.
The dipstick assay showed utility in a variety of clinical applications, including preliminary diagnosis of atypical FRDA patients, analysis of longitudinal frataxin
measurements, correlations with changes in neurological severity, patient response to HDAC inhibitor treatment, response to chemotherapy in an FRDA case
with comorbid osteosarcoma, and assessment of HDAC and SIRT gene polymorphisms on frataxin protein expression. Finally, we used Stable Isotope Labeling
with Essential nutrients in Cell culture (SILEC) methodology to assess metabolic changes in transfected cells as well as primary fibroblasts and platelets isolated
from FRDA patients. Using SILEC internal standards, we found that acetyl-CoA:succinyl-CoA ratios were significantly decreased in FRDA patients compared
to controls, consistent with in vitro siRNA knockdown models of frataxin. Changes in CoA profiles, coupled with isotopic tracer analysis using [U-13C6]-glucose and
[U-13C16]-palmitic acid, provided us with further insight into possible metabolic dysfunction in FRDA. Taken together, the results from this thesis show utility for frataxin measurements from peripheral tissues as a biomarker, and potentially provide researchers with a novel set of markers to assess metabolic dysfunction in unaffected tissues, not just in FRDA, but in any mitochondrial disorder.
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ABSTRACT 
 
MEASURING BIOMARKERS OF FRIEDREICH ATAXIA: IMPLICATIONS FOR 
CLINICAL RESEARCH 
Eric C. Deutsch 
David R. Lynch, MD, PhD 
 
Friedreich ataxia (FRDA) is a neurodegenerative disease caused by mutations in 
the frataxin (FXN) gene, resulting in reduced expression of the mitochondrial protein 
frataxin. While there currently is no cure for FRDA, our increasing understanding of the 
pathophysiology of disease has led to a surge in the development of potential treatments. 
As a result, there is a growing need for biological markers of disease progression and 
patient response to therapeutic intervention. In this thesis, we developed and validated a 
lateral flow “dipstick” immunoassay for the measurement of frataxin protein in multiple 
peripheral cell types. We measured significant differences in frataxin levels between 
controls, carriers, and FRDA patients, and found correlations between frataxin levels 
and GAA1 repeat length and age of onset. We then compared the utility of the dipstick 
assay as a population screening and diagnostic tool to a separate, Luminex xMAP-based 
immunoassay, and discuss the advantages and disadvantages of each assay in different 
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clinical settings. The dipstick assay showed utility in a variety of clinical applications, 
including preliminary diagnosis of atypical FRDA patients, analysis of longitudinal 
frataxin measurements, correlations with changes in neurological severity, patient 
response to HDAC inhibitor treatment, response to chemotherapy in an FRDA case with 
comorbid osteosarcoma, and assessment of HDAC and SIRT gene polymorphisms on 
frataxin protein expression. Finally, we used Stable Isotope Labeling with Essential 
nutrients in Cell culture (SILEC) methodology to assess metabolic changes in 
transfected cells as well as primary fibroblasts and platelets isolated from FRDA 
patients. Using SILEC internal standards, we found that acetyl-CoA:succinyl-CoA ratios 
were significantly decreased in FRDA patients compared to controls, consistent with in 
vitro siRNA knockdown models of frataxin. Changes in CoA profiles, coupled with 
isotopic tracer analysis using [U-13C6]-glucose and [U-13C16]-palmitic acid, provided us 
with further insight into possible metabolic dysfunction in FRDA. Taken together, the 
results from this thesis show utility for frataxin measurements from peripheral tissues as 
a biomarker, and potentially provide researchers with a novel set of markers to assess 
metabolic dysfunction in unaffected tissues, not just in FRDA, but in any mitochondrial 
disorder. 
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Chapter 1: Introduction to Friedreich ataxia and biomarker studies 
1.1 Friedreich ataxia: Pathogenesis and genetics 
Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder 
caused by mutations in the frataxin (FXN) gene resulting in decreased levels of the 
mitochondrial protein frataxin. FRDA has a prevalence of approximately 1:40,000-
1:50,000 people of Western European descent, making FRDA the most common 
inherited ataxia.111,114 FRDA was named after German physician Nikolaus Friedreich, 
who first reported the condition and its clinical and pathologic features in a series of 
patients during the 1860s and 1870s.70-73 FRDA typically presents before the age of 15, 
and is characterized by progressive limb and gait ataxia, sensory and proprioception loss, 
absent tendon reflexes, dysarthria, and ultimately loss of ambulation 10-15 years after 
onset of disease.60,82,151 In addition, many patients may present with progressive scoliosis, 
diabetes mellitus, foot deformity (pes cavus), pyramidal weakness, and optic atrophy.60,82 
Approximately 50-75% of FRDA patients develop cardiomyopathy or associated cardiac 
symptoms which contribute to premature death.82,206 Cognitive function was long thought 
to be preserved, but recent studies have suggested deficits in executive function and 
motor cognition from cerebellar impairment.46,119,140 Late-onset Friedreich ataxia (LOFA) 
is a subdivision of FRDA named for individuals first presenting with signs and symptoms 
after the age of 25, and is a result of a variation in disease-causing mutations discussed 
below. 
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Symptoms of FRDA are indicative of impaired proprioception; neurons involved 
in proprioceptive pathways express frataxin normally and show selective degeneration in 
FRDA.96,102 Proprioceptive sensory input from Golgi tendon organs and muscle spindles 
in skeletal muscle of lower extremities is transmitted rostrally by primary sensory axons 
with cell bodies in the dorsal root ganglia (DRG). Conscious proprioceptive input from 
the DRG projects to the posterior columns through the medulla and thalamus to the 
primary sensory cortex. Unconscious proprioceptive input from DRG afferents synapse 
on cell bodies in Clarke’s nucleus of the spinal cord, the major relay center for 
unconscious proprioception; axons from Clarke’s nucleus then project to the cerebellar 
cortex as mossy fibers. The pathologic hallmark of FRDA is selective degeneration of the 
posterior columns in the spinal cord, where axons of DRG sensory neurons are located. 
Early loss of large sensory neurons in the DRG is associated with deterioration of 
posterior columns, spinocerebellar and corticospinal tracts of the spinal cord, and the 
dentate nucleus in the cerebellum.102,136 Large diameter sensory neurons in the DRGs, 
which transmit proprioceptive information to the brain, selectively atrophy early in the 
time-course of disease, resulting in loss of posterior columns in the spinal cord.97,102 The 
sensory neuropathy in this region leads to the loss of vibration and position sense in 
FRDA patients that makes up the basis of their ataxia. Neuronal degeneration continues 
from large primary sensory neurons to Clarke’s nucleus which results in atrophy of 
spinocerebellar tracts relaying signals to the dentate nucleus in the cerebellum. 
Degeneration of afferent sensory inputs leads to the atrophy of the dentate nucleus. While 
much of the rest of the cerebellum is spared, recent imaging studies suggest cerebellar 
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damage may be more extensive than previously believed, though degeneration of white 
matter tracts and the cerebellar peduncles may simply be axon degeneration of dentate 
neurons.5,148,166 Progressive degeneration of distal corticospinal motor tracts is a late 
phenomenon, suggestive of a dying-back process, and leads to muscle weakness and 
extensor plantar responses.137,174 In contrast, scoliosis and absent sensory conduction 
action potentials are among the earliest signs of disease, and X-rays show thinning of the 
spinal column at first presentation, suggesting subclinical neurological deficits may exist 
long before presentation of symptoms and may be a result of early, nonprogressive loss 
of sensory neurons.82,125,179 
The heart and pancreas are also affected in many FRDA patients. Cardiac 
dysfunction often involves hypertrophic cardiomyopathy, including increased lateral 
ventricular and intraventricular septum thickness, and arrhythmias.130 While these signs 
of heart disease may be asymptomatic and do not correlate well with severity of ataxia, 
complications of cardiomyopathy are the leading contributors to early mortality.130,206 
Increased iron deposits in cardiomyocytes potentially lead to iron-induced mitochondrial 
oxidative damage followed by tissue necrosis.131,171 Heart failure with dilated 
cardiomyopathy was seen in deceased patients, representing end-stage progression of 
cardiac dysfunction.206 Approximately 10% of FRDA patients develop diabetes mellitus, 
and 20% have glucose intolerance. Diabetes in FRDA is complex and shares features 
with both Type I and Type II diabetes including autoimmune-independent destruction of 
pancreas islet cells, diabetic ketoacidosis, and peripheral insulin resistance.80,82,100,165,184 
Frataxin may contribute to oxidative stress and insulin release in response to glucose, as 
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frataxin expression in pancreatic islets from non-FRDA type II diabetes patients is much 
lower than control islets without type II diabetes, and correlates with glucose stimulation 
and nitrotyrosine.54 
Though the signs and symptoms of FRDA had been well-characterized since 
Friedreich’s initial reports, more than 125 years passed before the FXN gene (originally 
named X25) and the disease causing mutations were finally identified and mapped to 
chromosome 9q13.32 The majority (96-98%) of patients are homozygous for GAA 
trinucleotide repeat expansions of ~40-1700 repeats within the first intron of the FXN 
gene, with the repeat length on the shorter allele directly correlating with age of onset and 
disease severity.32,91,142,185 The rest of FRDA patients are compound heterozygotes with a 
GAA expansion on one allele and a point mutation or deletion on the other; these patients 
may exhibit atypical signs and symptoms of FRDA.47 Normal alleles contain fewer than 
40 repeats, though studies show a bimodal distribution of normal alleles; “small normal” 
alleles contain between six and 12 repeats, and “large normal” alleles contain between 13 
and 34 repeats.48,135 Normal alleles with >34 repeats exist, and are more prone to 
hyperexpansion upon transmission to the next generation, suggesting meiotic 
instability.48,135 Long GAA expansions are also unstable, leading to somatic mosaicism 
even within a single cell.17,50,51,134 
 GAA triplet repeat expansions lead to decreased FXN transcription, resulting in 
reduced levels of frataxin protein.32 This inhibition may be the result of formation of 
sticky or triplex DNA structures through self-association of long, uninterrupted stretches 
of GAA repeats preventing transcription elongation by RNA polymerase.175-177 In 
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addition, the formation of heterochromatin through reduced H3 and H4 acetylation and 
increased H3K9 methylation has been observed.6,34,87,101 Therefore, therapeutic strategies 
aimed to rescue frataxin levels through reversal of formation of complex DNA structures 
heterochromatin formation have emerged (see Chapter 1.3). 
1.2 Role of Frataxin protein 
 Human frataxin is a highly conserved, 210 amino acid (~17 kDa) protein encoded 
in the nucleus with an N-terminal mitochondrial targeting sequenced removed during a 
two-step maturation process.16,60,183 Human frataxin is initially cleaved by mitochondrial 
processing peptidase (MPP) between G41 and L42, removing the N-terminal 
mitochondrial targeting sequence.104 The location of the second cleavage site has been 
debated, but was recently shown to occur between K80 and S81, resulting in a 14.3 kDa 
mature protein (m81-FXN); a second mature form, cleaved between A55 and S56 (m56-
FXN), may occur in vitro or if the m81-FXN cleavage site is unavailable.40,183 GAA triplet 
repeat expansions in the first intron of the FXN gene result in impairment of FXN 
transcription instead of alteration of frataxin protein, which reduces levels of frataxin 
protein to 5-30% of normal.31 As a result, FRDA is a disease of frataxin deficiency, not 
of the complete absence of frataxin protein, as frataxin knockout mice are embryonic 
lethal.49 Frataxin is ubiquitously, but differentially, expressed in all mitochondria-
containing cell types, with expression being highest in metabolically demanding tissues 
of the spinal cord and heart, and intermediate in liver, skeletal muscle, cerebellum and 
pancreas.96,103 
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The exact function of frataxin remains unclear, but it is now understood that 
frataxin plays a major role in mitochondrial iron metabolism including iron binding, iron 
storage, iron-sulfur cluster (ISC) biosynthesis, and potential defense against reactive 
oxygen species (ROS).11,36,68,74,75 Reduced levels of frataxin results in decreased ISC 
biosynthesis, increased sensitivity to oxidative stress and increased mitochondrial iron 
(Figure 1).22,167,213 Studies in mouse and yeast models as well as in FRDA patient-derived 
cells have shown a deficiency in ISCs, implying a direct role for frataxin in biogenesis or 
assembly of ISCs.37,167,168 The interaction between frataxin and ISC biosynthesis is now 
well-characterized; frataxin enhances ISC assembly by acting as an iron chaperone to 
deliver iron to the ISCU/Nsf1 scaffolding complex, which in turn facilitates production of 
ISCs in an iron-dependent manner.3,42,59,106,152,167,188,205,210,218 ISCs are composed of iron 
and sulfur atoms that function as prosthetic groups for many different mitochondrial 
enzymes, including aconitase in the citric acid cycle and complexes I-III of the electron 
transport chain (ETC).15,168 Frataxin also serves as the iron chaperone that delivers iron to 
ferrochelatase, the enzyme responsible for catalyzing the final step in heme 
synthesis,85,217 and as the chaperone involved in protecting the ISC-containing enzyme 
aconitase from [4Fe-4S]2+ disassembly to the inactive [3Fe-4S]1+ core, a marker for 
protein oxidation in oxidative stress.25 Frataxin is believed to supply inactive aconitase 
with iron to reactivate the damaged ISC core.26,27 In addition, frataxin interacts with 
complex II of the ETC, suggesting a more direct role in mitochondrial energy 
production.79 Decreased ISC biosynthesis causes reduced activity of ISC-containing 
enzymes, including complexes I-III and aconitase, resulting in decreased energy 
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metabolism. As a result, impaired electron flow through the ETC causes increased 
leakage of electrons from the respiratory chain. These electrons directly react with 
molecular oxygen to form superoxide (O2-), which is converted to hydrogen peroxide 
(H2O2) by superoxide dismutase.  Reduced frataxin protein also leads to an increase in 
intramitochondrial iron levels without changing serum iron levels, increasing the amount 
of highly reactive Fe(II) that cannot be managed.157,214 This increased free mitochondrial 
ferrous iron reacts with H2O2 to produce damaging hydroxyl radicals in the Fenton 
reaction:4             
 
This results in frataxin-deficient cells from FRDA models being highly sensitive 
to oxidants.10,90,215 With less iron used for ISC synthesis, more Fe(II) is available to react 
with H2O2 for generation of toxic hydroxyl radicals, leading to ISC inactivation, lipid 
peroxidation, and protein, nucleic acid oxidation, and mitochondrial damage followed by 
eventual cell death.53 ROS-mediated cell death may be the foundation of the progression 
of neurological and muscular symptoms, ultimately leading to cardiomyopathy.147 Yeast 
and human frataxin both bind ferrous iron, and frataxin multimers are able to sequester 
and detoxify excess iron;2,35,41 this may protect the cell against an intramitochondrial iron 
overload, controlling the formation of highly reactive oxygen species through Fenton 
chemistry.30,75,99,144 Normal levels of frataxin protect DNA and the cell against iron-
induced oxidative damage by supplying the mitochondrion with Fe(II) while 
simultaneously preventing it from taking part in generation of oxidants.24,75,144 
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Overexpression of frataxin may protect the cell against ROS, while RNAi used to 
suppress frataxin expression in a Drosophila model showed that reduced frataxin 
enhanced oxidative inactivation of aconitase.109,169 There is evidence that frataxin may 
regulate antioxidant defenses that protect cells from oxidants.189 Although the 
contribution of each of these events to the pathology seen in the disease and why some 
cell types are spared over others remains unknown, it is likely that cell death is a result of 
mitochondrial dysfunction from impaired ISC-containing mitochondrial enzymes or 
decreased protection against iron-mediated oxidative stress. 
1.3 Therapeutic strategies in Friedreich ataxia 
 There is currently no approved treatment for FRDA in the United States, but 
several potential therapies aimed to correct mitochondrial dysfunction in FRDA or 
increase expression levels of frataxin are under development. These strategies include use 
of antioxidants and coenzyme Q analogs, iron chelators, histone deacetylase inhibitors, 
erythropoietin mimetics, and gene therapy. At present, such agents are all in various 
stages of evaluation for clinical use (Table 1). 
 Antioxidants were among the first class of agents investigated to correct 
mitochondrial dysfunction in FRDA, as oxidative stress was long believed to be involved 
in the pathology of disease. Coenzyme Q10 and vitamin E are common nonprescription 
agents used to reduce oxidative stress, though clinical studies show limited cardiac and 
neurologic benefit.43,83,110 One of the first drugs used in FRDA clinical trials since the 
discovery of the FXN gene was idebenone, a synthetic coenzyme Q10 analog. Like 
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coenzyme Q10, idebenone facilitates energy production as a free radical scavenger and as 
an electron carrier in the respiratory chain, and may rescue deficiencies in the ETC in 
FRDA.128 In 1999, Rustin et al. showed that idebenone not only protected heart 
homogenates against iron-induced lipoperoxidation and complex II inactivation, but also 
decreased left ventricular mass index in three FRDA patients.171 Several prospective 
open-label studies soon followed and confirmed the beneficial effect of idebenone on 
cardiomyopathy in FRDA with minimal neurological improvement.29,84,170 Randomized, 
placebo-controlled clinical trials have further investigated the long-term effects of 
idebenone on cardiac and neurological parameters, with mixed results.56,57, 
105,116,121,129,154,163 The 6-month phase III Idebenone effects On Neurological ICARS 
Assessments (IONIA) study and a 12-month extension (IONIA-E) study showed modest 
neurological improvement based on International Cooperative Ataxia Rating Scale 
(ICARS) and Friedreich Ataxia Rating Scale (FARS) scores when taking idebenone 
compared to placebo; only the change in ICARS in the IONIA-E study was statistically 
significant.116,129 However, no significant differences in cardiac function or left 
ventricular hypertrophy were seen between idebenone and placebo groups, suggesting a 
lack of benefit of idebenone over a 6-month period for cardiac function.105 Although 
idebenone is conditionally approved as treatment for FRDA in Canada, results from the 
above studies indicate that idebenone do not meet requirements for FDA approval in the 
United States, and there are no clinical trials presently being discussed; however, 
idebenone is well-tolerated and non-pharmaceutical grade drug remains available to 
FRDA patients as a nutritional supplement through online sources. 
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Recently, second generation coenzyme Q10 analogs have been developed and are 
undergoing evaluation for the treatment of FRDA. EPI-A0001 (alpha-tocopherolquinone) 
is a coenzyme Q10 analog with increased potency developed by Edison Pharmaceuticals 
aimed to restore mitochondrial function. A double-blind placebo-controlled phase II 
study was just completed evaluating the effect of EPI-A0001 on glucose regulation in 
FRDA.117 The primary endpoint of insulin resistance showed no changes with EPI-A0001 
compared to placebo, but statistically significant improvements in neurological function 
as measured by the FARS were seen in the low and high dose A0001 groups compared to 
placebo. The drug was well tolerated in both treatment arms, and additional clinical trials 
are in development to further investigate efficacy of EPI-A0001 in FRDA. Edison 
Pharmaceuticals has also sponsored an open-label phase II study to investigate EPI-743, a 
para-benzoquinone therapeutic with 1,000-10,000-fold more potency than coenzyme 
Q10 or idebenone, for the treatment of inherited mitochondrial disorders in 14 
individuals, including one patient with FRDA.62,190 While clinical and quality-of-life 
parameters were modified and the drug appears to be safe, more clinical trials are needed 
to evaluate benefit of EPI-743 in FRDA.62 
Intramitochondrial iron accumulation and a consequent increase in oxidative 
stress are likely involved in the pathogenesis of FRDA. As a result, iron chelating agents 
as a potential therapeutic in FRDA have received considerable attention in recent years. 
Current focus is on deferiprone, a chelating agent that crosses plasma and mitochondrial 
membranes and acts selectively on labile iron without depleting iron from ISC-containing 
enzymes.98,164,194 A pilot study was conducted in nine patients receiving low-dose 
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deferiprone for six months and demonstrated a positive effect on reducing brain iron 
accumulation as measured by magnetic resonance imaging.18 An open-label single-arm 
study investigated the effects of combined idebenone and low-dose deferiprone therapy 
on neurological and cardiac parameters over 11 months in twenty patients.207 
Electrocardiograph analysis revealed a decrease in left ventricular mass index and 
intraventricular septum thickness. Overall ICARS scores indicated stabilization in 
neurological dysfunction, although there was a divergence in ICARS subscores. A six 
month double-blind, placebo-controlled phase I/II study was recently completed to 
evaluate the safety and tolerability of low and high-dose deferiprone in FRDA patients. 
The results have not yet been published, but were reported at the 4th International 
Friedreich Ataxia Scientific Conference in 2011.8 High-dose deferiprone led to 
worsening ataxia in some patients, which improved upon discontinuation of the drug. 
Administration of low-dose deferiprone was associated with improvements in left 
ventricular mass index, and posture, gait and kinetic function Ataxia Rating Scale 
subscores in some patients with mild phenotype. Results of an open-label study 
examining the safety and effect on cardiac function of long-term deferiprone therapy 
(mean 2.8 ± 0.6 years) were also reported at the 4th International Friedreich Ataxia 
Scientific Conference in 2011.113 Seven out of nine patients with cardiac hypertrophy at 
baseline showed at least a significant improvement in intraventricular septum thickness, 
while the other two showed no significant changes. No patients experienced worsening of 
cardiac dysfunction or onset of new cardiac disease. Further clinical studies are needed to 
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evaluate the proper dosing regimen for maximizing therapeutic effect without resulting in 
further toxicity. 
Several different classes of drugs are in various stages of clinical investigation to 
assess their effects on frataxin protein levels. Resveratrol, an agent found in the skin of 
red grapes, potentially increases frataxin expression and improves mitochondrial function 
and the Murdoch Childrens Research Institute/FARA is currently recruiting subjects for 
an open label pilot study in Australia. Agonists and coactivators of the peroxisome 
proliferator-activated receptor gamma (PPARγ) pathway, used in treatment of diabetes, 
have been shown to alleviate oxidative stress and increase frataxin protein and mRNA 
levels in FRDA primary fibroblasts by two-fold, indicating a link between PPARγ 
coactivators and frataxin deficiency.45,122,123 Pioglitazone, a commercially available 
PPARγ agonist that crosses the blood-brain barrier, was proposed as a potential FRDA 
treatment in 2006, and a randomized placebo-controlled phase III trial is currently 
underway to investigate its efficacy on neurological function of FRDA patients over the 
course of two years.180 Frataxin protein levels can also be upregulated in a variety of cell 
types by in vivo treatment with interferon gamma, including primary cells from FRDA 
patients and DRG neurons from YG8R KIKO FRDA mice.203 Dr. Mark Payne has 
developed a transactivator of transcription (TAT) frataxin fusion protein to determine 
whether exogenous replacement of depleted frataxin in mitochondria can rescue 
phenotype. Initial studies in cultured FRDA fibroblasts and tissue-specific knockout 
mouse models show TAT-frataxin improved life span and cardiac function, and suggest 
protein replacement therapy may be a viable option for treatment in FRDA.208 Finally, 
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recombinant erythropoietin (rhuEPO) has been shown to increase frataxin protein 
expression without changing frataxin mRNA levels in primary FRDA fibroblasts and 
lymphoctyes through an unknown mechanism, suggesting a posttranscriptional effect of 
the drug.1,199 Clinical pilot and dose-response trials with rhuEPO showed a persistent 
increase in frataxin protein levels in patient lymphocytes along with a reduction in 
markers for oxidative stress and an improvement in neurological function based on 
various ataxia rating scales.19,20,138 A phase II trial showed a delayed and sustained 
increase in frataxin levels in FRDA peripheral blood mononuclear cells (PBMCs) after 
the administration of a single dose of Epoetin alfa without an effect on hematocrit, 
though these effects were not reproduced in a randomized placebo-controlled study.120,172 
A second phase II trial is planned to assess efficacy of Epoetin alfa on physical 
performance of FRDA patients. Currently, EPO mimetics are being developed to isolate 
the frataxin-increasing characteristics of the drug from the potentially hazardous 
erythropoietic properties, and to improve tissue penetrance and feasibility for oral dosing. 
 Alleviating the blockade of FXN transcription is another target of interest for 
FRDA drug development to potentially increase frataxin levels. A recent study showed 
DNA methylation around the GAA expansion correlated with frataxin expression and age 
of onset, suggesting a role for the epigenetic profile of FXN as a therapeutic target and a 
biomarker treatment response.64 Gene silencing in FRDA was shown to involve 
methylation of H3K9 and hypoacetylation at histones H3 and H4, which reversed with a 
treatment of HDAC inhibitors.87 Synthetic derivatives of the pimelic diphenylamide class 
of HDAC inhibitors from the Herman, et al. 2006 study were evaluated for effect on 
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frataxin expression levels, and resulted in increased frataxin mRNA and protein levels in 
mouse models and FRDA and carrier primary lymphocytes.38,158,159,216 Long-term 
treatment with pimelic o-aminobenzamide compound 109 in the YG8R KIKO FRDA 
mouse model increased histone acetylation, frataxin protein expression, and aconitase 
enzyme activity in the brain and reduced neuronal pathology of the DRG, suggesting a 
role for HDAC inhibitors in improving neurological phenotype.178 Preclinical studies 
continue to explore safety and efficacy of a new generation of HDAC inhibitors. 
While the treatments discussed here have shown some promise, none conclusively 
slow disease progression. As we learn more about the function of frataxin protein, 
mechanisms of FRDA pathology, and modifiers of frataxin expression, new potential 
therapeutic targets are rapidly emerging. Advancements in drug screening tools and 
assessment of outcome measures are needed to keep up with the current pace of drug 
development and clinical trials. 
1.4 Biomarkers and utility in Friedreich ataxia 
 As with any disease, there is a great need to measure FRDA disease progression 
and drug effects in preclinical and clinical studies. To measure the state of these 
biological processes, we use biomarkers. The NIH defines a biomarker as “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention”. Biomarkers are typically classified as Type 0 (natural history biomarkers), 
Type I (markers of drug activity), or Type II (surrogate outcomes), though oftentimes a 
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can be considered more than one type.132 While there is no formalized validation process 
for the use of biomarkers as surrogate measures, a set of biological, statistical, clinical, 
and risk/benefit criteria typically must be met. A valid biomarker should show evidence 
as a risk factor for the disease of interest, be consistent with pathophysiology, be involved 
with the causal pathway of disease, mirror changes in the prognosis, be correlated with 
clinical outcome, and should predict outcome in clinical trials for drugs of multiple 
pharmacologic classes.202 In the context of FRDA, affected tissues are clinically 
inaccessible, creating the need for surrogate markers from unaffected tissues and cells to 
reflect pathology.  Researchers typically examine all three types of biomarkers in FRDA 
studies, including markers of oxidative stress, cardiac and neurological dysfunction, 
changes in gene expression and frataxin protein levels all as differences from unaffected 
individuals at baseline, in response to pharmacological treatments, or as surrogates for 
patient-important outcomes. 
Cardiac dysfunction is the major contributor to premature death in FRDA, but 
survival analyses are not feasible as outcome measures in FRDA study populations.130,204 
Measures of cardiomyopathy, including left ventricular and intraventricular septum 
thickness, ejection fraction, and electrocardiogram parameters, are often used as 
surrogates for real, undesired clinical endpoints in natural history and clinical trial 
studies, and are the focus of several therapeutic strategies.105,149,161,207 While some 
therapies have shown modest improvements in cardiac parameters, it remains unclear 
whether these benefits are clinically significant in the context of patient survival. At the 
4th International Friedreich Ataxia Scientific Conference, we reported chronic elevations 
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in serum cardiac troponin in patients without acute coronary syndrome, suggesting a 
potential marker to identify those patients at risk for cardiac dysfunction.181 Further 
studies are needed to characterize serum markers of myocardial injury with the hope that 
they may provide insight into progression of cardiomyopathy and present researchers 
with an opportunity to initiate therapeutic intervention before onset of symptoms. 
As we understand more about the pathogenesis of FRDA and enroll more patients 
for clinical trials, the need to quantify clinical symptoms and the impact of treatments 
becomes more important; unfortunately, affected cell types in FRDA are clinically 
inaccessible, so surrogate measures of neurological function and progression are required. 
While there is no gold standard to measure disease progression in FRDA, studies have 
begun to evaluate various ataxia rating scales for validity and accuracy in assessment of 
FRDA. The International Cooperative Ataxia Rating Scale (ICARS) was originally 
designed for cerebellar ataxias, but has also found an application in FRDA studies.204 The 
ICARS ranges from 1 to 100, and contains subscores for posture and gait disturbances, 
kinetic functions, speech disorders, and oculomotor disorders.33 Debate remains whether 
the ICARS is a reliable measure of FRDA, and further validity testing is required before 
the ICARS can be recommended for clinical trials.33,192 The Friedreich Ataxia Rating 
Scale (FARS) was developed as a more appropriate scale for FRDA, and correlates well 
with activities of daily living, functional disability, and disease duration.115 The FARS 
contains five subscores (bulbar, lower and upper extremities, peripheral portion, and 
upright stability) and is scored from 0 to 125, with higher scores representing more 
severe disease progression.69 Both the ICARS and FARS are still used to assess disease 
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progression, but the FARS has shown greater utility in clinical trial settings, as fewer 
patients are required to demonstrate the same effect of an intervention.65 The Scale for 
the Assessment and Rating of Ataxia (SARA) is a short-form neurological exam 
developed for use in dominantly inherited ataxia, but correlates well with the FARS and 
has shown some utility as a compact test for use in FRDA clinical trials.20,28,182,200,211 It 
remains unknown whether biological markers exist that can predict disease progression 
as measured by any of these rating scales for natural history or clinical trial studies. 
At the molecular level, studies have focused on markers of potential consequences 
of reduced frataxin as a measure of FRDA pathology or pharmacological response. These 
include activities of ISC-containing enzymes, urinary and intracellular markers of 
oxidative stress, mitochondrial iron levels, mitochondrial DNA levels, and 31phosphorus 
magnetic resonance spectroscopy as a measure of energy production;22,23,61,86,110,153 
however, these measures have been ineffective in assessing mitochondrial function from 
peripheral tissues in large scale clinical studies. As FRDA is caused by depletion of 
frataxin protein, measurement of frataxin itself could potentially be useful to assess 
severity of disease. Traditionally, frataxin protein levels were measured through Western 
blot or enzyme-linked immunosorbent assay (ELISA) analysis from patient-derived cells, 
which is not ideal for rapid quantification in a clinical research setting.19,31 An 
electrochemiluminescence assay was developed to quantify frataxin from lymphocytes 
and fibroblasts, but the procedure is labor-intensive and untested in cell types collected 
noninvasively, and is limited by a narrow working range across different cell types and 
tissues.197 This same assay, however, did show correlation of frataxin levels in blood and 
  
18 
 
skeletal muscle in seven FRDA patients, endorsing frataxin measurements from an 
unaffected tissue as a valid biomarker.139 MitoSciences Inc. (now part of Abcam) has 
developed a series of lateral-flow immunoassays to measure protein and enzyme activity 
levels, including frataxin, without isolating or purifying mitochondria.212 Initial studies 
showed significant differences in frataxin levels between lymphoblastoid cells derived 
from a small set of FRDA patients, known carriers, and controls, and provided a 
reproducible way to measure frataxin protein levels from a variety of cell and tissue 
types, including buccal cells and whole blood.212 
Here, we have expanded upon these findings by measuring frataxin protein from 
large numbers of controls, known carriers, and FRDA patients in multiple cell types and 
correlating frataxin levels with measures of disease severity. In Chapter 2, we present two 
different techniques for rapidly measuring frataxin protein in unaffected cell types, and in 
Chapter 3 we discuss applications for these methodologies in screening and diagnostic 
settings. Finally, in Chapter 4 we examine acyl-CoA profiles in cells isolated from FRDA 
patients and uncover a potential set of mitochondrial markers for metabolic 
rearrangement from peripheral tissues.  
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Figure 1 – The role of frataxin protein within the mitochondrion. Pathways in green 
indicate decreased function in FRDA, and pathways in red indicate increased activity in 
FRDA (adapted from Pandolfo, Nat Clin Pract Neurol., 4, 86-96 (2008).  
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Table 1 – Research pipeline in FRDA. Data gathered from the Friedreich Ataxia 
Research Alliance and www.clinicaltrials.gov. 
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Chapter 2: Utilization of immunoassays for frataxin protein measurement 
2.1 Abstract 
 While there currently is no cure for FRDA, several potential therapies are in the 
treatment pipeline, revealing the need for biological and surrogate markers of disease 
progression and response to treatment, including the measurement of frataxin protein 
itself. Traditionally, frataxin protein levels could only be measured through Western blot 
or ELISA analysis from patient-derived cells, which is not ideal for rapid quantification 
in a clinical research setting. In this chapter, we have utilized two separate assays to 
measure frataxin from patient samples. We first used a lateral flow immunoassay to 
measure frataxin protein levels in controls, known carriers, and FRDA patients in 
PBMCs, platelets, whole blood, and buccal cells. Significant differences were seen 
between groups in all cell types, and the results of the assay were shown to be 
reproducible and contain minimal variability. We also used a previously validated 
Luminex xMAP-based immunoassay to quantify frataxin protein levels in dried blood 
spots from FRDA patients, carriers, and controls. Significant differences were again seen 
between these groups, with cutoff values established for population screening purposes. 
ROC curve analyses revealed favorable sensitivity and specificity ratios for both assays. 
These assays demonstrate potential diagnostic utility and for measuring baseline frataxin 
levels in screening or clinical trial settings. 
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2.2 Introduction 
 FRDA is caused by mutations in the FXN gene encoding the mitochondrial 
protein, frataxin. These mutations result in decreased expression of frataxin, which causes 
the clinical manifestations of the disease. Approximately 96% of individuals with FRDA 
have homozygous expansions of the GAA trinucleotide repeat in the first intron of the 
FXN gene, while the majority of the remaining 4% of FRDA patients have the 
trinucleotide expansion on one allele and a point mutation or deletion on the second 
allele.32 Traditionally, FRDA has been genetically diagnosed for the presence of the GAA 
expansion; however, this test cannot be used to effectively monitor treatment or 
efficiently utilized for population screening. An immunoassay measuring frataxin protein 
levels from easily accessible peripheral tissues would be ideal for both diagnosis as well 
as clinical monitoring in FRDA patients. Frataxin protein was typically measured using 
Western blot or ELISA analysis, neither of which is feasible for rapid measurements from 
large numbers of samples in clinical research settings. A few studies with small sample sizes 
have focused on means to quantify frataxin from patient samples; however, these procedures 
typically are untested in many peripheral cell types used in clinical studies, and are 
limited by narrow working ranges.139,197,198
 Recently, Mitosciences (now part of Abcam) developed a lateral flow “dipstick” 
immunoassay to measure levels of mitochondrial proteins, including frataxin, without the 
 With increased knowledge of the 
pathophysiology of FRDA and the growing number of clinical trials accompanying it, 
there is an increased need for clinically accessible biomarkers that follow disease severity 
and patient response to pharmacological intervention. 
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need for isolating mitochondria (Figure 2.1). This assay is based on the principle of the 
sandwich ELISA, and uses two different antibodies directed against the mature form of 
frataxin protein.  Samples are loaded into the bottom of a 96-well plate, where gold-
conjugated frataxin antibodies bind to the frataxin protein within the sample. As the 
sample wicks up the dipstick, frataxin is immunocaptured onto the nitrocellulose portion 
of the dipstick by a second antibody, giving rise to a pink line in the capture zone. The 
signal intensity corresponds with the amount of frataxin in the sample and is measured by 
a dipstick reader. Initial studies used the assay to show differences in frataxin levels 
between lymphoblastoid cells derived from a small set of FRDA patients, carriers, and 
controls, and provided a reproducible way to measure frataxin protein levels from a 
variety of cell and tissue types, including buccal cells and whole blood.212 However, until 
this point, studies measuring frataxin protein in large numbers of whole blood and buccal 
cell samples had not been conducted. 
 Our hypothesis was that an assay for the rapid measurement of frataxin protein 
from peripheral tissues could then be used for clinical monitoring as well as screening 
and diagnostic testing purposes in large numbers of FRDA patients and their families. In 
this chapter, we validate and utilize the lateral flow immunoassay for the measurement of 
differences in frataxin levels in multiple peripheral cell types collected by noninvasive 
and minimally invasive means from controls, carriers, and FRDA patients. We show 
correlations between frataxin levels and classical measures of disease severity, including 
GAA1 repeat length and age of onset. We also assess frataxin protein levels in patients 
with point mutations and LOFA patients, and discuss their effects on how to design the 
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immunoassay as a screening tool. Finally, we collaborate with Dr. Devin Oglesbee at the 
Mayo Clinic and use an xMAP-based Luminex immunoassay to measure frataxin protein 
from dried blood spot (DBS) samples, and discuss the advantages and disadvantages of 
using either immunoassay in different clinical settings. 
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2.3 Materials and Methods 
2.3.1 Patients  
 These studies had approval by the International Review Board at all participating 
institutions. All subjects provided written informed consent before participating in study 
procedures. 
Clinical and demographic information, including molecular confirmation of FXN 
gene mutations, was provided through an ongoing longitudinal natural history study on 
FRDA.69 Samples were collected from a majority of these patients at the University of 
Pennsylvania/Children's Hospital of Philadelphia, the University of California at Los 
Angeles Medical Center, Emory University, University of Florida, and other patients 
referred to physicians practicing at these and other institutions. A series of patients with 
other disorders also participated as a “diseased” control to account for referral bias. These 
subjects had other ataxia or movement disorders in which FRDA has been ruled out by 
clinical and genetic criteria. Carriers and normal healthy volunteers also provided 
samples for frataxin analysis (Table 2). 
2.3.2 Sample preparation 
PBMCs and some platelet samples isolated from FRDA patients and normal 
healthy volunteers were separated through differential centrifugation and Ficoll gradients 
(GE Healthcare) and were generously provided by Dr. Jean-Emmanuel Sarry and Dr. 
Mary Selak for this study.186 
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To isolate platelets in lab, blood was collected in 8.5 mL glass acid citrate 
dextrose Vacutainer tubes (BD Biosciences) and transferred into 15 mL centrifuge tubes. 
Blood was spun at 129 g in a swinging bucket centrifuge for 15 min with no brakes. The 
upper platelet rich plasma (PRP) layer was transferred to a fresh tube and spun at 341 g in 
a swinging bucket centrifuge for 15 min with no brakes to pellet platelets. Platelet pellets 
were resuspended in 1 mL PBS (GIBCO) and stored at -80oC until use. 
Whole blood from controls, carriers, and patients was collected in K2 EDTA BD 
Vacutainer tubes (REF 367844) and frozen immediately at -80oC until use. Whole blood 
protein was extracted by mixing 1 volume of whole blood to 3 volumes of ice cold 
extraction buffer A (Abcam/MitoSciences) for 15 min at 4oC. Samples were 
microcentrifuged at 16,100 g for 10 min at 4oC, and the supernatant was transferred to a 
fresh microcentrifuge tube and stored at -80oC until use. Samples were further diluted 
1:10 in ice cold extraction buffer A (Abcam/MitoSciences) for frataxin quantity analysis 
before use. 
Buccal cells were harvested using MasterAmp Buccal Swab Brushes (Epicentre) 
by firmly pressing a brush against the inner cheek and swabbed while twirling for 30 
seconds on each cheek. Both brushes were then immersed in the same microcentrifuge 
tube containing 500 µL of ice cold extraction buffer A (Abcam/MitoSciences) and 
twirled gently in the extraction buffer to dislodge the cells. To extract protein from the 
buccal cells, the microcentrifuge tubes were incubated on ice for 20 minutes with 
intermittent vortexing, and then microcentrifuged at 16,100 g for 10 min at 4oC, and the 
supernatant was transferred to a fresh microcentrifuge tube and stored at -80oC until use. 
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Protein concentration was determined using the BCA protein assay according to the 
manufacturer’s protocol (Pierce) before frataxin protein quantity analysis. 
2.3.3 Lateral flow immunoassay protocol 
Frataxin protein quantity dipstick assay kits (Abcam/MitoSciences, MSF31) were 
used to measure frataxin levels in PBMCs, platelets, whole blood, and buccal cells 
(Figure 2.1). To determine the working range of the lateral flow immunoassay (Figure 
A.1), a standard curve was generated using recombinant frataxin protein 
(Abcam/MitoSciences). Standard curves using representative control samples were run to 
determine appropriate amounts of sample to use within the working range of the assay for 
all cell types (Figure A.2). For measurement from buccal cells, PBMCs, and platelets, 5 
or 10 µg of total cellular protein in 25 µl of ice cold extraction buffer A 
(Abcam/MitoSciences) was mixed with 25 µl 2x blocking buffer B 
(Abcam/MitoSciences) and added to individual wells on a 96-well plate with gold-
conjugated mAb at the bottom of each well. Whole blood was further diluted 1:10 in ice 
cold extraction buffer A (Abcam/MitoSciences) from the initial preparation and 25 µl 
was mixed with 25 µl 2x blocking buffer (Sigma) before added to individual wells. After 
samples were allowed to equilibrate with the antibodies, dipsticks were inserted into the 
well and sample was allowed to wick up the membrane, where frataxin was 
immunocaptured onto designated capture zones on the dipstick. The dipsticks were 
washed in 30 µl of wash buffer C (Abcam/MitoSciences) and allowed to dry before 
analysis. Capture zones on developed dipsticks were quantified with a Hamamatsu 
immunochromato reader (MS1000 Dipstick reader). Raw mABS results were corrected 
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for protein concentration and normalized to the control goat α-mouse IgG band (internal 
positive control), and the data were expressed as percentages of the average controls run 
on the same assay. 
2.3.4 Luminex xMAP-based immunoassay protocol 
 For each subject, 50 µl of whole blood was spotted on each circle of Protein Saver 
903 Cards (Whatman), and cards were allowed to dry before analysis. Protein was eluted 
from dried blood spots, mixed with frataxin antibody-coupled microspheres, and 
analyzed for frataxin content using the Luminex 200 analyzer at the Mayo Clinic (Figure 
2.2). Calibration of frataxin content was performed using purified human frataxin 
(courtesy of Dr. Grazia Isaya at the Mayo Clinic). 
2.3.5 SDS-Page and western blot analysis 
After the protein concentration of samples was determined through a BCA assay 
(Pierce), samples were run on 14% acrylamide gels at 120 V for 2 hours and transferred 
onto 0.45 µM nitrocellulose membranes at 100 V for 1 hour (Bio-Rad). Blots were 
blocked in 3% milk in TBSt for 1 hour, incubated at 4oC in primary antibody overnight 
(1:2000 α-frataxin: Abcam/MitoSciences, 1:4000 α-actin: Sigma), and then in secondary 
antibody for 1 hour (α-rabbit, α-mouse 1:2000, Cell Signaling). Blots were incubated in 
Supersignal West Dura Chemiluminescent Substrate (Thermo Scientific) for 1-2 min and 
exposed to Hyblot CL film (Denville Scientific). Protein levels were quantitated by 
scanning densiometry analysis using NIH ImageJ software. 
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2.3.6 Statistical analysis 
Data analysis was performed using STATA SE 11 software and MS Office Excel 
2007. Frataxin levels in patient samples were expressed as percentage of average control 
for that assay. Student’s t-test was used to compare means in PBMCs, and one-way 
ANOVA followed by Scheffe’s post hoc analysis was used to compare means in 
platelets, whole blood, and buccal cells. All frataxin levels as measured by dipstick 
assays were expressed as a percentage of average controls, and frataxin levels measured 
by Luminex assay were expressed as ng/mL whole blood. Simple and multiple regression 
analysis were conducted to analyze relationships between frataxin levels and multiple 
independent variables. 
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2.4 Results 
2.4.1 Lateral flow immunoassays distinguish frataxin protein levels between controls, 
known carriers, and FRDA samples across multiple cell types 
Platelets and peripheral blood mononuclear cells (PBMCs) represent extractable 
cell types rich in mitochondrial that may potentially be useful for frataxin measurement 
from FRDA patients. As part of a collaborative study with Jean-Emmanuel Sarry and 
Mary Selak to assess subclinical abnormalities in unaffected cells, we measured frataxin 
protein levels from isolated platelets and PBMCs using the lateral flow immunoassay.186 
We did not have sufficient PBMCs to run a proper standard curve, so we chose to load 5 
µg of each sample per well, which is in the middle of the working range suggested by 
MitoSciences.212 We measured significant differences in frataxin levels between control 
and FRDA PBMCs (p < 0.001), with mean FRDA PBMC frataxin levels at 37.6% of 
average controls (Figure 2.3A). A standard curve using platelets isolated from a 
representative control showed that the dipstick assay remained in the linear range through 
20 µg of platelet protein (Figure A.2). Based on this result, we loaded 10 µg of platelet 
protein to ensure we conserved platelet samples and were in the center of the working 
range for platelets and recombinant frataxin. Typical control platelets contained 
approximately 15 pg frataxin/µg total protein based on calculations from the recombinant 
frataxin standard curve (Figure A.1). We found significant differences between control 
and FRDA platelets (p < 0.001), with mean FRDA platelet frataxin levels equal to 38.1% 
of average controls (Figure 2.3B). In addition, we measured frataxin levels in platelets 
isolated from three carriers; while the average frataxin level from these samples was in 
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between controls and carriers (59.6%), the difference was not statistically significant 
because of the small sample size. Clinical information was not obtained for these 
samples, so we were unable to correlate frataxin protein levels with other disease 
parameters. 
While we see clear differences in frataxin levels between controls and FRDA 
patients in cells isolated from whole blood, isolation and storage of platelets and PBMCs 
for frataxin measurement is difficult in large settings where numerous samples are being 
collected. We eliminated the isolation step and measured frataxin levels directly from 
whole blood. Based on the results of a standard curve (Figure A.2), we loaded the 
equivalent of 2.5 µl of whole blood per well (25 µl diluted 1:10), which was in the 
middle of the working range of the assay for whole blood and recombinant frataxin. This 
corresponded to approximately 65 pg frataxin/µl whole blood for control samples, based 
on the recombinant frataxin standard curve (Figure A.1). We measured frataxin protein 
levels in whole blood drawn from large numbers of controls (n=68), known carriers 
(n=107), and FRDA patients (n=242), which were divided into LOFA (n=28), point 
mutation (PM, n=4), and the remaining FRDA patients (n=207). FRDA patients in this 
cohort covered a wide spectrum of FRDA disease severity (Table A.1). Frataxin protein 
was significantly reduced in carriers (69.1% of control, p < 0.001) and FRDA patients 
(26.4% of control, p < 0.001), with significant decreases also seen in LOFA and PM 
FRDA patients (Figure 2.4).  While there is some overlap between controls, carriers, and 
FRDA patients suggestive of variability between individuals, none of the 95% confidence 
intervals or interquartile ranges between groups overlap (Figure 2.4). The increased 
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frataxin levels in LOFA patients (54.6% of control) suggest a relationship between age of 
onset and frataxin protein levels. In addition to strong correlations between age of onset 
and GAA1 repeat length (R2 = 0.665, p < 0.001), we found strong correlations between 
age of onset and frataxin (R2 = 0.407, p < 0.001) and GAA1 and frataxin (R2 = 0.415, p < 
0.001), suggesting frataxin measurements from whole blood correlate with measures of 
disease severity (Figure 2.5). We then performed ROC analysis by measured frataxin 
levels in whole blood to assess how well the dipstick assay could correctly identify a 
sample as having “disease” or “no disease”. We constructed these curves in two different 
ways to ask whether we wanted to test to identify FRDA patients from controls and 
carriers, or have the test identify both carriers and FRDA patients together separated from 
controls. Both analyses performed very well, with an area under the curve greater than 
0.955 for each potential screening method (Figure 2.6A,B). Based on these ROC curves 
and mean frataxin levels measured in our samples, we established a set of classification 
criteria for the dipstick assay to label an unknown sample as “control”, “carrier/potential 
FRDA”, or “FRDA”; we used frataxin levels of greater than 85% of control as our 
“control” classifier, 45-85% of control as our “carrier/potential FRDA” classifier, and 
<45% of control as our “FRDA” classifier. We then used these classifiers to determine 
which screening method was most accurate and clinically useful (Figure 2.6C).  
Screening to identify carriers and FRDA patients yielded the highest sensitivity (0.936) 
and very high positive predictive value (PPV, 0.967) out of our two screening methods, 
indicating that identifying both carriers and FRDA patients from the test will result in the 
fewest false negatives (Table A.2). The negative predictive value (NPV) was low (0.722), 
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due to the relatively low number of control samples assayed compared to carriers and 
FRDA patients. Taken together, these results suggest that using the dipstick assay to 
identify patients and carriers based on frataxin levels in whole blood may be a valid 
complimentary tool for population screening or diagnosis in large numbers of individuals. 
While collection of whole blood is relatively convenient in a clinical setting, 
protein extraction from cheek swab samples represents a true, noninvasive sampling 
technique that can be utilized in any setting, which may be important for multicenter 
clinical studies or visits at patients’ homes. Here, we examined the potential utility of 
measuring frataxin protein from buccal cell extracts using the lateral flow immunoassay. 
The assay remained in the linear range through 20 µg of buccal cell protein (Figure A.3), 
but we decided to use 10 µg based on the amount of protein we could conceivably extract 
from a typical cheek swab sample and load in a 25 µl volume. Based on our recombinant 
frataxin standard curve (Figure A.1), typical control buccal cell extracts contained 
approximately 10 pg frataxin/µg total cheek swab protein. Similarly to whole blood, we 
collected buccal cell extracts from a large number of controls (n=90), known carriers 
(n=245), and FRDA patients which were broken up into LOFA (n=23), point mutation 
(PM, n=11), and the remaining FRDA patients (n=271). These patients also encompassed 
a large spectrum of FRDA disease severity as evidenced by the wide range in age of 
onset and GAA1/GAA2 repeat length (Table A.3). We measured significant decreases in 
frataxin levels in buccal cells from known carriers (58.5% of control, p < 0.001) and 
FRDA patients (20.1% of control, p < 0.001); in addition, we also measured frataxin 
from a group of non-FRDA patients with other movements disorders (MD) as another 
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control group (n=19), and found no significant changes in frataxin compared to 
unaffected controls (110.0% of control, p = 0.332), confirming that reductions in frataxin 
protein are associated with FRDA (Figure 2.7). We see overlap between control, carrier, 
and FRDA patient frataxin protein levels in buccal cells, but note that the interquartile 
ranges and 95% confidence intervals between each group do not overlap. We separated 
out the LOFA patients and found that LOFA frataxin levels in buccal cells (41.4% of 
control) were significantly higher compared to normal FRDA or PM FRDA patient levels 
(p < 0.001). Excluding a patient with an R165C mutation, buccal cell frataxin levels from 
FRDA patients with missense mutations correlated with GAA2 repeat length (R2 = 0.578, 
p = 0.011) and were not statistically different than those from classic FRDA patients. In 
spite of the severe phenotype, the elevated frataxin levels in our R165C patients is in 
agreement with reports of R165P patients presenting with increased frataxin protein and 
mRNA, suggesting that location of a missense mutation may contribute to severity of 
disease.173 As expected, we found a strong correlation between age of onset and GAA1 
repeat length in the total FRDA population (Figure 2.8A, R2 = 0.620, p < 0.001). Frataxin 
levels also showed modest correlations with age of onset (Figure 2.8B, R2 = 0.229, p < 
0.001) and GAA1 repeat length (Figure 2.8C, R2 = 0.240, p < 0.001). We carried out two 
ROC curve analyses to plot sensitivities and specificities of measured frataxin levels in 
buccal cells as previously described in whole blood. Both analyses again performed well, 
with an area under the curve greater than 0.930 for each potential screening method 
(Figure 2.9A,B). Using the ROC curves and frataxin levels measured in cheek swab 
samples, another set of classification criteria was created for the dipstick assay to label an 
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unknown cheek swab sample as “control”, “carrier/potential FRDA”, or “FRDA”; here, 
frataxin levels of greater than 80% of control was our “control” classifier, 40-80% of 
control was our “carrier/potential FRDA” classifier, and <40% of control was our 
“FRDA” classifier. We then used these classifiers to construct 2x2 tables to calculate 
which screening method was most accurate and clinically useful based on the above 
criteria (Figure 2.9C). As with whole blood, the PPV (0.960) and sensitivity (0.918) were 
highest when screening for FRDA patients and carriers in cheek swab samples, with a 
relatively low NPV (0.662) from a small control population (Table A.4). These values are 
comparable to those from whole blood; thus, measuring frataxin protein from cheek swab 
samples to identify carriers and FRDA patients may be a viable screening tool in large 
clinical settings. 
We investigated the reliability and validity of the dipstick assay by measuring 
recovery of recombinant frataxin and assessing the variation inherent to the assay itself. 
In both whole blood and cheek swab samples, approximately 95% or greater recovery of 
up to 100 pg recombinant frataxin was achieved, demonstrating that no other components 
of the samples significantly interfered or enhanced the measured frataxin absorbance 
(Table A.5). Reproducibility of the lateral flow immunoassay was evaluated by 
determining intra-assay, inter-assay, and inter-sample variation within the working range 
of cheek swabs and whole blood collected from a representative control (Table A.6). The 
dipstick assay was reproducible within the working range with low mean intra-assay 
(<6%), inter-assay (<8%), and inter-sample (3.2% and 7.3%, whole blood and cheek 
swab, respectively) coefficient of variation (CV) values. CV values were higher in cheek 
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swab samples than whole blood; however, the standard deviations were similar in 
magnitude between cheek swabs and whole blood, but mean cheek swab frataxin mABS 
were lower, i.e. small changes in absolute values result in larger percent CV changes. We 
compared frataxin levels from current control whole blood and cheek swab samples to 
those collected from the sample individual within the previous four years (Table A.7). 
While all samples showed small intra-assay variation, the cheek swab sample mABS 
values varied from year to year and were all significantly different from the current cheek 
swab sample frataxin levels. In contrast, whole blood samples were all similar to each 
other, with no significant differences found.  
Taken together, these data suggest that the dipstick assay can measure differences 
in frataxin values between controls, known carriers, and FRDA patients in multiple 
peripheral cell types. When used to identify carrier and FRDA patient samples from a 
population, the assay exhibited a low rate of false negatives and a high PPV and, thus, 
may be a useful tool for population screening and diagnosis. There is high recovery and 
low variation associated with the assay; however, whole blood samples may be better 
suited for long-term storage and analysis compared to cheek swab samples. 
2.4.2 The quantitative Luminex xMAP-based assay shows utility as a screening and 
diagnostic tool 
 In collaboration with Dr. Devin Oglesbee at the Mayo Clinic, we also measured 
frataxin protein from DBS eluates using the Luminex xMAP-based immunoassay for 
potential use as a screening tool (Figure 2.2). At the 4th International Friedreich Ataxia 
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Scientific Conference in 2011, Dr. Oglesbee presented clinical validation of the Luminex 
immunoassay for measuring frataxin levels in DBS, including recovery, reproducibility, 
and stability data pertaining to DBS storage.141 To determine how applicable the 
Luminex immunoassay is for population screening compared to the dipstick assays, we 
measured frataxin protein via Luminex assay in 23 controls, 76 carriers, and 141 FRDA 
patients (Table A.8). Age of onset correlated strongly with GAA1 (R2 = 0.713, p < 0.001) 
in these patients, as did frataxin levels (R2 = 0.568, p < 0.001) as measured by Luminex 
assay in DBS (Figure 2.10A,B). Of those individuals, we measured frataxin levels in 
parallel via dipstick assay in 17 controls, 54 carriers, and 90 FRDA patients (Table A.8). 
Frataxin levels measured by Luminex assay correlated strongly with frataxin levels as 
measured by dipstick assay (R2 = 0.742, p < 0.001, Figure 2.10C), demonstrating 
reproducibility of frataxin measurements across multiple assays. 
As seen in Chapter 2.4.1, we measured reduced frataxin levels in carriers (mean 
70.6% of control) and FRDA patients (mean 35.7% of control) using the dipstick assay 
(Figure 2.11A). Reduced frataxin levels were also seen in carriers (15.2 ng/mL) and 
FRDA patients (6.9 ng/mL) relative to controls (28.5 ng/mL) as measured by the 
Luminex assay (Figure 2.11B); frataxin levels were quantified by comparing 
fluorescence intensity to a standard curve using purified human frataxin. Differences in 
frataxin levels between controls, carriers, and FRDA patients in both assays were 
statistically significant (p < 0.001). 
To determine how well the Luminex assay performs as a population screening 
tool, we conducted two separate ROC analyses on the measured frataxin values to 
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determine which individuals we wanted to identify from our test, and compared the 
results to values from dipstick assay measurements (Figure 2.12A-D). In each 
circumstance for both assays, the area under the ROC curve was greater than 0.915, 
signifying that each may be an accurate and potentially worthwhile test. The area under 
the curve was higher for the dipstick assay than the Luminex assay, although fewer 
samples were analyzed by dipstick analysis. Based on the shape of the ROC curves and 
mean values from our frataxin measurements, we chose specific frataxin levels as cutoff 
points for both assays to classify each sample as a “control”, “carrier/potential FRDA 
patient”, or “FRDA patient”. Using these classification criteria, we created 2x2 tables to 
examine the operating characteristics and predictive value of each assay for each question 
we wanted our screening tool to answer (Figure 2.13A,B).  Confirming our findings in 
Chapter 2.4.1, screening for FRDA patients and carriers versus unaffected controls 
offered the highest or close to the highest sensitivities and PPVs in both the dipstick and 
Luminex assays (Table A.9). For identification of carriers/FRDA patients, the Luminex 
assay had higher sensitivity (0.963 versus 0.910), specificity (0.957 versus 0.765), PPV 
(0.995 versus 0.970), and NPV (0.733 versus 0.500) values compared to the dipstick 
assay. NPV values were relatively low both assays again, which is likely attributed to the 
relatively low numbers of control samples analyzed. These results suggest that frataxin 
measurements from eluted DBS by the Luminex assay to identify carriers and FRDA 
patients are more accurate than the dipstick assay, with lower false positive and false 
negative rates. We note that both assays perform well, and the method of testing used will 
depend on the study context, the clinical setting, and the composition of the study cohort.  
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2.5 Discussion 
2.5.1 The lateral flow immunoassay shows utility in rapidly measuring frataxin protein 
from a variety of cell types 
 In this chapter, we first used a lateral flow “dipstick” immunoassay to measure 
differences in frataxin protein levels between control, known carriers, and FRDA patients 
in multiple peripheal cell types. Studies have shown that frataxin protein levels from 
peripheral tissues correlate not only with frataxin mRNA, but with frataxin levels in 
skeletal muscle in FRDA patients, suggesting that these measurements may be useful as a 
valid marker of FRDA disease in affected tissues.139,173 We focused our studies on 
measurements from whole blood and cheek swab samples, as they represent two easily 
extracted peripheral tissues for the measurement of biomarkers in disease. In each of 
these cell types, we found significant differences in frataxin levels between controls, 
known carriers, and FRDA patients; we also measured frataxin levels in LOFA patients 
and PM patients to elucidate differences, if any, between them and classic FRDA patients 
with two GAA repeat expansions and have found significantly higher levels in LOFA 
patients compared to the remaining FRDA patients. We measured frataxin levels from 
PM patients and found that they did not differ significantly from classic FRDA patient 
levels (Table A.10). Frataxin levels in both tissue types correlated with age of onset and 
GAA1 repeat length, suggesting that frataxin levels may be an appropriate marker of 
disease severity.67 
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 Based on ROC curve analyses and our own frataxin measurement data, we 
generated a set of criteria for classifying measured whole blood and cheek swab samples 
as a control, carrier, or FRDA patient. There were different contexts to consider in using 
the dipstick assay as a population test. For example, one could only be interested in 
identifying FRDA patients in a population, and ignore all of the individuals in the control 
or carrier range, or one could identify all carrier and FRDA samples, and ignore all of 
those individuals with frataxin levels in the control range. Based on our ROC curve 
analyses, the dipstick test is more useful for identifying both FRDA subjects and carriers. 
Sensitivities and PPVs were highest in this scenario for both whole blood and cheek 
swabs and were comparable between the two cell types. This method of screening avoids 
excluding FRDA patients with higher frataxin levels, particularly LOFA patients and 
some PM patients, while still maintaining a low false negative rate. In a large-scale 
diagnostic setting, a positive result for this test would indicate an individual is either a 
carrier or FRDA patient, and could then be subjected to a DNA test to analyze potential 
GAA expansions. There may be a few control subjects with lower frataxin levels in the 
carrier range; however, in this approach one is less concerned about false positives than 
false negatives when screening for FRDA. While we do minimize the rate of false 
positives, a positive test on this screening test would only result in a blood draw for DNA 
sequencing, a relatively minor procedure. This approach focuses on high positive 
predictive value and high sensitivity to reduce the risk of “missing” any FRDA patients in 
a screen. We found a low NPV for both cheek swabs and whole blood; however, this 
value is heavily influenced by the number of unaffected controls in the study. Cheek 
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swab and whole blood samples were collected from much fewer unaffected controls than 
carriers and FRDA patients, which in turn underestimate the NPV of the test. In future 
clinical studies, the number of unaffected controls sampled will be much larger relative to 
the number of false positives found, producing a higher NPV value. 
We originally ran standard curves with recombinant frataxin alongside standard 
curves of all cell types used for frataxin measurements to not only determine working 
concentrations of each cell type, but to quantify absolute frataxin protein levels as well. 
Interestingly, commercial recombinant frataxin varied slightly by lot number, so we 
expressed data as a percentage of average control frataxin levels instead of absolute 
frataxin levels. This method allows us to make comparisons between multiple samples of 
the same individual or samples in a group of individuals assuming the same group of 
control samples are used to normalize the rest of the samples.  
Whole blood and cheek swab samples are easily extractable tissues from 
individuals with their own advantages and disadvantages in clinical studies. We showed 
that intra-assay, inter-assay, and inter-sample variation is low in whole blood and cheek 
swab samples, though we see smaller CV values in whole blood. The relatively higher 
variation in cheek swab samples may be attributed to a number of factors; these include 
possible presence of extracellular protein in the cheek swab sample, additional error from 
protein concentration measurements, and increased CVs from lower absolute frataxin 
absorbance values compared to whole blood in spite of similar standard deviation values. 
In addition, long-term storage of control samples at -80°C increased variation between 
samples to a greater degree in cheek swab samples than in whole blood. There also 
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appears to be a “learning curve” associated with collecting cheek swabs samples from 
individuals. Samples collected from the Philadelphia area by our own clinical 
coordinators typically have a protein concentration between 1.0 and 2.5 µg/µl; samples 
collected from off-site locations have a higher percentage of unusable samples – samples 
with a total protein concentration of less than 0.4 µg/µl, which results in less than 10 µg 
protein in a 25 µl volume required for the dipstick assay. It is possible that shipment of 
samples could have resulted in a reduction of sample quality, but this phenomenon is not 
seen when our clinical coordinators travel to other sites to collect samples to ship back to 
Philadelphia. Furthermore, protein concentrations of cheek swabs do increase as 
researchers become accustomed to collecting samples. It is important that researchers at 
other institutions educated properly on correct techniques for cheek swab sample 
collection to avoid loss of scientifically valuable samples. While frataxin measurements 
in whole blood have stronger correlations with age of onset and GAA1 repeat length, less 
sample and assay variation, and greater long-term storage stability than cheek swab 
samples, the convenient and non-invasive nature of cheek swab collection may present 
researchers with a viable alternative in the correct setting; therefore choice of tissue used 
for frataxin measurements will depend on the type of study and the materials available. 
Taken together, we have shown in this chapter that frataxin measurements from whole 
blood or cheek swabs by dipstick assay may be useful population screening and 
diagnostic tools and are associated with acceptable levels of variation. 
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2.5.2 The Luminex xMAP-based assay may be a useful multicenter screening tool in 
whole blood 
In addition to our work with the dipstick assay, we also collaborated with Dr. 
Devin Oglesbee at the Mayo Clinic to quantify frataxin protein with an xMAP-based 
Luminex assay from eluted DBS (Figure 2.2) in controls, carriers, and patients to 
determine its utility as a population screening and diagnostic tool compared to the lateral 
flow dipstick immunoassay. Frataxin levels from DBS as measured by the Luminex assay 
correlated strongly with levels from whole blood measured by the dipstick assay (Figure 
2.10C), and were significantly different between controls, carriers, and FRDA patients 
(Figure 2.11). ROC curve analyses indicated both assays had areas under the ROC curve 
greater than 0.910 (Figure 2.12); however, the Luminex assay demonstrated a higher 
sensitivity, specificity, NPV, and PPV compared to the dipstick assay when identifying 
carriers and FRDA patients from a cohort (Figure 2.13). 
We found inconsistencies in total frataxin levels between the dipstick assay and 
Luminex assay when comparing to standard curves based on recombinant frataxin. 
Frataxin levels as measured by dipstick assay were approximately two-fold higher 
compared to measurements by Luminex assay (~65 pg/µl vs ~30 pg/µl). We were using 
commercial recombinant frataxin for our standard curves which may have had impurities 
in it, thereby artificially elevating frataxin levels in our samples. The Mayo Clinic 
purified and validated their own human frataxin for use in generating a standard curve for 
the Luminex assay; therefore, we expressed all values measured by the dipstick assay as a 
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percentage of the average controls to place an emphasis on relative amounts of frataxin 
between controls, known carriers, and FRDA patients. 
There are advantages and disadvantages of using the Luminex assay compared to 
the dipstick assay. While both assays performed well in correctly classifying whole blood 
or DBS samples, the Luminex assay scored higher for sensitivity, specificity, NPV, and 
PPV. The increased accuracy and reduced rate of false negatives and false positives make 
this assay attractive for researchers with access to the Luminex technology. In addition, 
the nature of the assay allows for multiplexing of tests to investigate multiple markers of 
disease. In the future, these could be markers that refine differences between controls, 
carriers, and FRDA patients, or markers for other aspects of disease, including insulin 
resistance, mitochondrial dysfunction, or myocardial injury. Only a small amount of 
blood is required for the Luminex assay, which makes it ideal for a newborn screening 
tool to potentially diagnose infants before onset of symptoms. Early diagnosis of FRDA 
opens up new cohorts for pharmacological intervention, which may lead to better 
prognosis. In contrast, the dipstick assay is clinically useful in multiple cell types, 
including the rapidly and non-invasively collected buccal cell extracts from cheek swabs. 
Measurements from multiple cheek swab samples are ideal in clinical trial settings where 
the patient population may be younger children that are adverse to potentially painful 
blood draws; family members of FRDA patients and normal healthy volunteers are also 
more likely to donate a cheek swab sample than a whole blood sample. The dipstick 
assay is relatively easy and less time-consuming to perform compared to the Luminex 
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assay, and the dipsticks can be stored for long periods of time before recording 
absorbance measurements.  
In this chapter, we have shown that both assays are useful for population 
screening and diagnostic purposes and have their own advantages associated with them; 
the choice of assay used will therefore depend on the study question of interest, the 
composition of the study population, and the study design. 
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Figure 2.1 – Schematic for lateral flow immunoassay. (A) Samples are loaded into the 
bottom of a 96-well plate, where gold-conjugated frataxin antibodies bind to the frataxin 
in the sample. As the sample flows up the dipstick, frataxin is immunocaptured onto the 
nitrocellulose portion of the dipstick and can be quantified. (B) Sample dipsticks from 
frataxin measurement in buccal cell lysate, and calculations used to express frataxin 
levels for our studies. FXN: frataxin, GAM: goat α-mouse. 
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Table 2 – Demographic information for whole blood and cheek swab samples collected 
from volunteers for frataxin analysis by dipsticks. Detailed information was not obtained 
from individuals donating platelets or PBMCs. 
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Figure 2.2 – Luminex xMAP-based immunoassay flow chart. Dried blood spot (DBS) 
sample eluate was incubated with microspheres coated with a frataxin antibody, and 
quantified by measuring fluorescence intensity using a Luminex 200 analyzer. 
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Figure 2.3 – Frataxin levels measured using the lateral flow immunoassay from freshly 
isolated PBMCs and platelets. (A) Frataxin levels in FRDA PBMCs were significantly 
reduced compared to controls (37.6%, p < 0.001). (B) Frataxin levels were reduced in 
platelets isolated from carriers and FRDA patients (59.6% and 38.1% of control, 
respectively). Patient levels were significantly lower than controls (p < 0.001). 
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Figure 2.4 – Frataxin levels measured using the lateral flow immunoassay from whole 
blood. Significant differences were measured between controls and all other groups (p < 
0.001), carriers and all other groups (p < 0.05 for LOFA, p < 0.001 for all others), and 
FRDA patients and LOFA patients (p < 0.001). LOFA: late-onset Friedreich ataxia, PM: 
point mutation FRDA patients. 
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Figure 2.5 – Frataxin correlates with age of onset and GAA1 repeat length in whole blood 
isolated from FRDA patients. (A) Similarly to cheek swab samples, age of onset 
correlated with GAA1 in our study population (R2 = 0.665, p < 0.001). (B) Frataxin 
showed stronger associations with age of onset (R2 = 0.407, p < 0.001) and (C) GAA1 (R2 
= 0.415, p < 0.001) than in buccal cells. 
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Figure 2.6 – ROC curves and classification data from frataxin measurements by dipstick 
assay in whole blood. ROC curves for separation of (A) controls from carriers and FRDA 
patients and (B) controls and carriers from FRDA patients. (C) 2x2 tables based on 
chosen values for classifying samples as “control”, “carrier/potential FRDA”, or 
“FRDA”. CTL: control, CR: Carrier. 
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Figure 2.7 – Frataxin levels measured using the lateral flow immunoassay from cheek 
swab samples. Significant differences were measured between controls and all other 
groups (p < 0.001) except non-FRDA MD patients, carriers and all other groups (p < 
0.001) except LOFA patients (p < 0.05), and FRDA patients and LOFA patients (p < 
0.001). LOFA: late-onset Friedreich ataxia, PM: point mutation FRDA patients, non-
FRDA MD: non-FRDA movement disorder patients.
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Figure 2.8 – Frataxin correlates with age of onset and GAA1 repeat length in cheek swab 
samples. (A) Confirming previous reports, age of onset correlated with GAA1 in our 
study population (R2 = 0.620, p < 0.001). (B) Frataxin showed a moderate association 
with age of onset (R2 = 0.229, p < 0.001) and (C) GAA1 (R2 = 0.240, p < 0.001). 
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Figure 2.9 – ROC curves and classification data from frataxin measurements by dipstick 
assay in buccal cells. ROC curves for separation of (A) controls from carriers and FRDA 
patients and (B) controls and carriers from FRDA patients. (C) 2x2 tables based on 
chosen values for classifying samples as “control”, “carrier/potential FRDA”, or 
“FRDA”. CTL: control, CR: Carrier.
  
56 
 
 
 
 
 
Figure 2.10 – Correlations from frataxin measurements in FRDA patients by Luminex 
assay. (A) In our study population, age of onset correlated strongly with GAA1 (R2 = 
0.713, p < 0.001). (B) Frataxin levels as measured by the Luminex xMAP-based assay 
correlated strongly with GAA1 (R2 = 0.568, p < 0.001). (C) Frataxin levels from whole 
blood as measured by the Luminex xMAP-based assay correlated strongly with frataxin 
levels measured using the dipstick assay (R2 = 0.742, p < 0.001).
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Figure 2.11 – Frataxin boxplots comparing frataxin measurement between dipstick and 
Luminex xMAP-based assays. Significant differences (p < 0.001 between all groups) in 
frataxin levels between controls, carriers and FRDA patients were measured by dipstick 
assay (A) and Luminex assay (B). 
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Figure 2.12 – Receiver operating characteristic (ROC) curves based on measuring 
frataxin from whole blood with the Luminex xMAP-based immoassay (A,C) and dipstick 
assay (B,D). ROC curves demonstrate utility as a screening tool based on the area under 
the curve when separating (A,B) controls from carriers and FRDA patients and (C,D) 
controls and carriers from FRDA patients. 
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Figure 2.13 – Classification data based on cutoff values from ROC curves for (A) 
Luminex assay and (B) dipstick assay. CTL: control, CR: Carrier.
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Chapter 3: Applications of frataxin measurements in diagnostic and clinical settings 
3.1 Abstract 
 A critical aspect of drug development is the ability to measure changes in 
response to therapy. In the last chapter, we demonstrated the ability of the lateral flow 
immunoassay to measure differences in frataxin levels between controls, known carriers, 
and FRDA patients; however, the sensitivity of the assay to measure changes in frataxin 
levels in response to pharmacological interventions or between different genetic 
conditions remained untested. In this chapter, we discuss several applications of utilizing 
the lateral flow immunoassays in clinical research settings; these include measuring 
frataxin levels in atypical patients, measuring changes in response to HDAC inhibitor 
treatment, measuring changes in response to combined methotrexate, doxorubicin 
(adriamycin), and cisplatin (MAP) chemotherapy in a FRDA patient with comorbid 
osteosarcoma, and analyzing effect of HDAC polymorphisms on frataxin levels and 
disease phenotype. We found that frataxin protein levels remained relatively stable over 
time in controls and FRDA patients, and the lateral flow immunoassay was sensitive 
enough to detect changes in frataxin levels in response to drug treatment. We also noted 
that frataxin levels showed a slight trend with SIRT6 mutation status, but that these 
differences were not significant when accounting for GAA1 repeat length, age and sex, 
and likely do not account for all of change in FRDA phenotype seen. Nevertheless, the 
lateral flow immunoassay may be a useful complementary diagnostic tool for atypical 
patients or for measuring changes in frataxin levels in clinical trial settings. Additionally, 
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while single nucleotide polymorphism (SNP) analysis in SIRT genes was inconclusive, 
we may be able to analyze other modifiers of frataxin using our immunoassays. 
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3.2 Introduction 
3.2.1 Friedreich ataxia patients with atypical genetic composition 
 Approximately 97% of FRDA patients are homozygous for the GAA expansion in 
the FXN gene; the majority of the remaining patients are compound heterozygotes with 
an expanded GAA repeat on one allele and a point mutation on the other allele.32,47,150 
Both are traditionally associated with decreased levels of frataxin, though this has not 
been applied to large heterogeneous cohorts. Recently, several heterozygous exonic 
deletions have been reported, expanding the known disease-causing spectrum and 
indicating that other patients likely carry deleterious mutations that remain to be 
characterized.7,63,196,221,223 Here, we describe a subset of atypical FRDA patients without 
two known disease-causing mutations. We measured frataxin protein levels via lateral 
flow immunoassay in these patients, followed by MLPA analysis on those individuals 
with levels in the FRDA patient range to uncover previously undetected deletions. We 
also examine frataxin levels in fractionated whole blood from an individual with a 2delT 
start codon mutation to investigate the effect of the mutation on frataxin levels in 
different cell types. We show that the lateral flow immunoassay has diagnostic utility in 
atypical FRDA patients and may be a reasonable complementary tool to use in clinical 
settings. As the spectrum for disease-causing mutations continues to expand, we believe 
these patients should be under consideration when developing or prescribing potential 
therapies for treatment. 
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3.2.2 HDAC inhibitors as a potential therapy in Friedreich ataxia 
Individuals who are heterozygous carriers of the triplet GAA expansion express 
levels of frataxin that are reduced by approximately 50% compared to normal levels, yet 
they manifest no clinical symptoms. This suggests that therapeutic approaches that 
increase frataxin may be effective even if frataxin is raised only to the level of a carrier.  
Small molecule HDAC inhibitor compounds increase histone acetylation at the frataxin 
locus and increase frataxin mRNA and protein levels.87 Increases in frataxin mRNA and 
protein have been observed in vitro using primary lymphocytes isolated from patient 
blood and in FRDA-derived induced pluripotent stem cells (iPS) and neural precursor 
cells.159 Beneficial effects of HDAC inhibitors have also been documented in animal 
models of FRDA.158,159,178 
Performance of later stage clinical trials in FRDA with such agents will require 
biological markers of drug response. A variety of clinical measures including 
examination based scales and performance measure composites have been validated in 
FRDA, but their sensitivity to change as reflected in natural history data is limited.65 
Similarly, biomarkers of FRDA are at present limited. Assessment of peripheral frataxin 
levels capable of measuring effects of HDAC inhibitors has been utilized, but many of 
the practical features of its uses, including short-term and long-term variability 
independent of therapy, have not yet been defined.55,139,197,212 In addition, data linking 
serial change in neurological outcome measures with frataxin level, confirming frataxin 
levels as appropriate targets in the disease, have not yet been obtained. 
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In this section, we characterize the stability of frataxin levels over time, the 
correlation of frataxin protein levels with disease severity and progression, and the 
contribution of frataxin from different components of whole blood. We also report 
measurable increases in frataxin mRNA and protein in PBMCs following HDAC 
inhibitor treatment, confirming the utility of frataxin protein immunoassays in clinical 
trial settings. 
3.2.3 MAP chemotherapy and connection to pathophysiology of Friedreich ataxia 
While no cure currently exists for FRDA, several potential therapies that aim to 
restore frataxin protein or mRNA levels (histone deacetylase inhibitors, gene therapy, and 
erythropoietin mimetics) are being investigated.1,87,105,123,198 Interestingly, cisplatin, a 
DNA-crosslinking drug used in cancer chemotherapy, can induce expression of both 
frataxin mRNA and protein in cisplatin-resistant ovarian carcinoma cell lines to promote 
defense mechanisms against reactive oxygen species damage.78 For trials of such agents, 
it will be helpful to measure biomarkers to assess disease severity or effectiveness of 
potential treatments. Clinically affected tissues are largely inaccessible, so alternatives 
are needed. Because frataxin protein measured from peripheral blood parallels levels in 
clinically affected tissue, the use of whole blood for frataxin measurements is clinically 
relevant as a biomarker.139 
As the FRDA population becomes more defined, patients are being identified with 
significant concomitant medical illnesses. Some of these diseases and/or their treatments 
may interact pathophysiologically with FRDA. Here, we describe an individual with 
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FRDA receiving an 8-month course of methotrexate, doxorubicin (adriamycin), and 
cisplatin (MAP) chemotherapy. This therapy may intersect the pathophysiology of FRDA 
in two ways: first, in the association of increased frataxin levels in vitro with cisplatin 
treatment, and second, in the reactive oxygen species-based cardiac disease associated 
with doxorubicin, which could potentially synergize with the mitochondrial dysfunction 
of FRDA to cause major adverse effects. Anthracycline antibiotics, including 
doxorubicin, are known to cause dose-limiting cardiotoxicity, which may exacerbate the 
already existent cardiac dysfunction in FRDA patients.187,191 We sought to determine 
whether MAP chemotherapy had an effect on FRDA disease state and measured serial 
frataxin levels and blood counts to assess changes throughout the course of treatment.  
3.2.4 SNP analysis and potential modifiers of frataxin protein 
 HDAC inhibitors are potentially useful therapeutics for FRDA based on in vivo 
and in vitro data from animal models and cells isolated from FRDA patients.87,158,159,178 
Polymorphisms in HDAC genes may result in increased frataxin expression or 
improvement of FRDA phenotype. Mammalian sirtuins comprise a family of seven 
NAD+-dependent deacetylases implicated in the regulation of transcription, DNA repair, 
cell survival, cellular stress responses, and metabolism.81 Within this family, SIRT1, 
SIRT6, and SIRT7 are localized to the nucleus, SIRT3, SIRT4, and SIRT5 are 
mitochondrial, and SIRT2 is cytosolic.81 SIRT6 is involved in regulation of gene 
expression, fatty acid metabolism, DNA repair, genome stabilization, and lifespan in 
mice.81 SIRT3 knockout mice exhibit global mitochondrial hyperacetylation and 
accelerated signs of metabolic syndrome, indicating that SIRT3 is a major mitochondrial 
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deacetylase involved in regulating energy and intermediary metabolism.58,88,112 Frataxin 
deficiency has been associated with a decrease in mitochondrial acetylated proteins and 
altered NAD+/NADH ratios, implying a role for impaired NAD+-dependent deacetylase 
activity in FRDA.138,193 Heart homogenates from conditional knockout mouse models of 
FRDA also show hyperacetylation that develops progressively with cardiac hypertrophy, 
suggesting that impaired SIRT3 deacetylase activity may contribute to lethal 
cardiomyopathy in FRDA.209 Marcia Haigis reported at the 4th International Friedreich’s 
Ataxia Scientific Conference that overexpression of SIRT3 partially rescued FRDA-like 
phenotype in hFXNI154F mutant mammalian cells, decreased mitochondrial ROS 
production, and rescued proliferation defects.95 Both sirtuins show deacetylase activity at 
specific sites on H3 and H4, which are hypoacetylated near the GAA repeat expansion. 
Taken together, these data suggest that sirtuins may represent a potential new target for 
pharmacological intervention in treating FRDA through reversible protein acetylation. 
We hypothesized that non-synonymous SNPs in HDAC genes may predict FRDA 
phenotype and frataxin protein levels. In this section, we analyzed 46 non-synonymous 
SNPs in HDAC and SIRT genes from a DNA repository and correlated mutation status 
with measures of FRDA disease severity based on the clinical database of the 
Collaborative Clinical Research Network in Friedreich’s Ataxia. We measured frataxin 
protein via lateral flow immunoassay and investigated the relationship between frataxin 
levels and mutation status in selected HDAC genes. We hypothesized that frataxin 
protein levels would follow mutation status in those HDAC genes that predict FRDA 
disease severity. 
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3.3 Materials and Methods 
3.3.1 Study approval and informed consent 
These studies had approval by the International Review Board at all participating 
institutions. All subjects provided written informed consent before participating in study 
procedures. 
3.3.2 Analysis of atypical FRDA patients 
Whole blood and cheek swab samples were collected for frataxin analysis from 
individuals with FRDA-like phenotype who did not carry known pathogenic mutations 
on each allele. Frataxin protein levels were measured by lateral flow immunoassay as 
described in Chapter 2, and those individuals with values in the low FRDA patient range 
were screened for possible deletions by MLPA analysis. 
MLPA analysis was conducted in the laboratory of Dr. Cathy Stolle. Genomic 
DNA was extracted from peripheral blood using an AutoGenFlex STAR automated DNA 
extractor (AutoGen, Inc.) or a commercially available kit (Genetra Systems, Inc.) 
according to manufacturer's instructions. 
Deletion/duplication analysis by MLPA (multiplex ligation-dependent probe 
amplification assay) of the FXN gene was performed according to manufacturer's 
instructions with a commercially available probe mix (P316-B1, Recessive Ataxias, MRC 
Holland, Amsterdam, the Netherlands). In brief, 200 ng of genomic DNA in a final 
volume of 5 μl was heated for 5 min at 98°C. After cooling to room temperature, 1.5 μl of 
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the probe mix and 1.5 μl SALSA hybridization buffer were added to each sample, 
followed by heat denaturation (1 min at 95°C) and hybridization (16 hours at 60°C). 
Ligation was performed by adding 32 μl of ligation mix at 54°C for 15 min and the 
reaction was stopped by incubating for 5 min at 98°C. PCR amplification was carried out 
for 35 cycles in a final volume of 40 μl. PCR products were separated by capillary 
electrophoresis using an ABI 3130Xl (Applied Biosystems). An internal size standard 
LIZ 600 was used (Applied Biosystems). Two female controls were processed along with 
patient samples. Data analysis was performed using GeneMarker v 1.6 (SoftGenetics, 
USA). Threshold values were set at 0.75–1.3 for normals, 0.4–0.65 for deletions and 1.4–
1.6 for duplications. For normalization two female control samples were used. 
For analysis of a family carrying a start codon deletion (2delT), whole blood was 
collected in K2 EDTA BD Vacutainer tubes (REF 367844) and transferred to 15 mL 
conical tubes. Blood was spun at 129 g in a swing bucket centrifuge for 15 min with no 
brakes. The middle buffy layer was removed and saved to prevent contamination of other 
fractions with WBCs. The upper platelet rich plasma (PRP) layer was transferred to a 
fresh tube and spun at 341 g in a swing bucket centrifuge for 15 min with no brakes to 
pellet platelets. An aliquot of plasma was saved for analysis and stored at -80oC. The 
platelet pellet was resuspended in 500 µL PBS and stored at -80oC until use. The 
remaining RBC pellet was spun at 341 g in a swing bucket centrifuge for 15 min with no 
brakes to remove any residual plasma. RBC pellets were stored at -80oC until use. All 
frataxin measurements were performed using the lateral flow immunoassay, the Luminex 
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assay, and western blot analysis in cheek swab, whole blood, and platelet samples as 
previously described in Chapter 2. 
3.3.3 Short-term frataxin stability and reproducibility analysis 
Whole blood from thirty-one FRDA patients at the Children’s Hospital of 
Philadelphia was collected in K2 EDTA BD Vacutainer tubes (REF 367844) at baseline, 
2 weeks, and 4 weeks for short-term frataxin stability and reproducibility analysis and 
stored at -80oC until use. Blood from normal healthy volunteers was collected on a 
weekly basis throughout the study. Total protein was extracted by mixing 1 volume of 
whole blood to 3 volumes of ice cold extraction buffer A (Abcam/MitoSciences) for 15 
min at 4oC. Samples were microcentrifuged 5 min at 13,000 g and cleared supernatant 
was saved for analysis. Samples were further diluted 1:10 in extraction buffer A 
(Abcam/MitoSciences) for frataxin measurement by lateral flow immunoassay as 
described in Chapter 2. We used paired t-tests to measure differences in frataxin levels 
between patient visits. Analysis of long-term frataxin stability and effect of HDAC 
inhibitor treatment on PBMCs was conducted by Repligen Corporation. 
3.3.4 Clinical monitoring in a FRDA patient with osteogenic sarcoma 
A woman with FRDA at the University of California at Los Angeles Medical 
Center was diagnosed with osteosarcoma by bone biopsy after an X-ray and MRI 
following knee pain revealed a possible tumor. This patient underwent six months of 
combined chemotherapy at the Kaiser Permanente Medical Center. All patient 
information used in this study was provided by her neurologist, oncologist, and family. 
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Frataxin protein levels were measured throughout the study from whole blood and cheek 
swab samples as described in Chapter 2. Blood cell counts and cardiac parameters were 
also assessed throughout the duration of the study at the Kaiser Permanente Medical 
Center, and changes in parameters were assessed using linear regression. 
3.3.5 Effect of HDAC gene polymorphisms on FRDA phenotype 
We used the Collaborative Clinical Research Network in Friedreich’s Ataxia 
clinical database to analyze the association between HDAC gene polymorphisms and 
features of FRDA including age of onset, FARS score, performance measures Z2 
(composite of reciprocal-scored 9-hole peg test and reciprocal-scored timed 25-foot walk 
z-scores) and Z3 (composite of Z2 and low-contrast letter acuity vision test z-score), and 
presence of diabetes, cardiomyopathy or scoliosis. Genomic DNA from 458 subjects 
across multiple sites was genotyped at 46 non-synonymous SNPs in HDAC genes 
(HDAC10, HDAC5, SIRT3, SIRT5, SIRT6), and SNP scores were assigned based on 
mutation status. Frataxin protein levels were measured from whole blood and cheek swab 
samples as described in Chapter 2 for as many patients as possible. Simple and multiple 
regression analyses were used to analyze relationships between SNP scores and measures 
of disease phenotype accounting for GAA repeat length, age at sample collection, and 
age of onset. 
3.3.6 Statistical analysis 
Data analysis was performed using STATA SE 11 software and MS Office Excel 
2007. Frataxin levels were expressed as percentage of average control. 
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3.4 Results 
3.4.1 Immunoassays exhibit diagnostic utility in patients with atypical Friedreich ataxia 
Approximately 96-98% of all FRDA patients carry an expanded GAA repeat on 
both alleles of the FXN gene, while the remaining 2-4% are compound heterozygotes for 
an expanded GAA repeat on one allele and a deleterious point mutation within the FXN 
gene on the other allele.32 During the course of our work, we identified ten patients with 
FRDA-like phenotype who did not have typical pathogenic mutations identified on each 
allele, including two individuals with only a single point mutation. Seven of these 
patients had reduced frataxin protein levels as detected in buccal cell samples by lateral 
flow immunoassay, with six in the low FRDA patient range (Table 3.1). For the purpose 
of our study, we classified these individuals as “atypical” FRDA patients. 
We screened six of these atypical patients for a possible deletion in the FXN gene 
using MLPA analysis (Table 3.1). Four of the six patients tested were negative for any 
deletions within the FXN gene; however, two patients carried novel deletions 
encompassing FXN exons (Figure 3.1). In one patient (P.A.001), we identified a 
heterozygous deletion that included exons 2 and 3 as indicated by a decrease in 
amplification of the associated primer pairs (Figure 3.1A). A second patient (P.A.005) 
was found to carry a heterozygous exon 5 deletion (Figure 3.1B). These mutations both 
appear to be deleterious as indicated by low frataxin levels and FRDA-like phenotype the 
patients display. No changes were seen in peak amplitudes of genes not involved in 
FRDA (SETX and APTX). These data further confirm the wide spectrum of deleterious 
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FXN mutations and indicate that other patients likely carry deleterious mutations that 
remain to be characterized. 
As shown in Chapter 2, frataxin protein levels measured in cheek swab samples 
correlate well with levels measured from whole blood; however, it might be possible that 
certain mutations may lead to an altered frataxin protein that is upregulated in cells with a 
high turnover rate. Curiously, we consistently found a large difference between whole 
blood (62.8% of control) and buccal cell (4.5% of control) frataxin protein levels in one 
severely affected atypical patient (P.A.002) that has no expanded alleles and a 2delT start 
codon mutation on one allele (Table 3.1). To determine the source of extra frataxin in 
blood, we fractionated fresh whole blood from P.A.002 as well as his parents and two 
siblings and measured frataxin from buccal cells, whole blood, platelets, and the RBC 
pellet (Figure 3.2A). We found that the RBC pellet, which is assumed to contain very low 
levels of mitochondria, was responsible for the elevated frataxin level seen in whole 
blood in P.A.002 (Figure 3.2B). Interestingly, the father (who also carries the 2delT 
mutation) and one sibling of P.A.002 also have elevated whole blood (139.9% and 
128.6% of average control, respectively) and RBC pellet frataxin levels (127.1% and 
112.7% of average control, respectively), suggesting that the start codon mutation in FXN 
leads to increased immunoreactive frataxin in red blood cells through an unknown 
mechanism. 
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3.4.2 Frataxin protein levels remain stable over time and are increased in response to 
HADC inhibitor therapy 
In Chapter 2, we found that frataxin levels measured in whole blood from a 
control sample were stable over the course of three years (Table A.7). In order to evaluate 
what effect potential therapies would have on frataxin levels over baseline changes, we 
sought to determine whether frataxin levels in FRDA patients were also unchanging, or if 
they varied with normal progression of disease. First, we examined short-term stability of 
frataxin in whole blood from FRDA patients, by measuring frataxin levels via dipstick 
assay from a cohort of 31 FRDA patients at 0, 2, and 4 week visits, and using paired t-
tests to compare frataxin levels between visits (Figure 3.3). The cohort covered a wide 
spectrum of disease severity, with age of onset ranging from 5-41, and GAA1 repeat 
length ranging from 126-901 repeats. As in Chapter 2, we found correlations between age 
of onset and GAA1 repeat length (R2 = 0.794, p < 0.001, Figure 3.3A), GAA1 repeat 
length and frataxin (R2 = 0.583, p < 0.001), and age of onset and frataxin (R2 = 0.385, p < 
0.001). Based on paired t-test comparisons, frataxin levels did not differ between 0 and 2-
week visits (p = 0.892), 2 and 4-week visits (p = 0.191), or 0 and 4-week visits (p = 
0.257) for this cohort (Figure 3.3B). Similarly, Dr. Jim Rusche’s group at Repligen 
Corporation has reported that weekly frataxin protein and mRNA measurements from 
five FRDA patients and five related carriers do not vary significantly over a 15-week 
period (data unpublished). To assess long-term stability of frataxin in FRDA patients, we 
followed frataxin levels from a representative patient over the course of three years and 
found that levels did not significantly change between measurements during this time 
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(Table A.11). Taken together, we show that frataxin levels measured in whole blood from 
FRDA patients remain stable over a length of time predicted to be relevant for clinical 
trial studies.  
Since frataxin levels appear to be stable over time and correlate well with GAA1 
repeat length and age of onset, we investigated whether frataxin levels would predict 
severity of disease as measured by FARS scores. In a linear regression model accounting 
for patient age and sex, we found a significant relationship between frataxin levels in 
whole blood with baseline FARS scores (n=94, p < 0.001, R2 = 0.245). This finding was 
supported by the correlation between GAA1 and baseline FARS scores (p < 0.001, R2 = 
0.441), which suggests patients with longer GAA repeats and lower frataxin levels 
present with a more severe neurological phenotype. 
We then investigated whether frataxin levels would predict the rate of disease 
progression, as measured by rate of change in FARS scores. FARS scores were shown to 
increase at an average rate of 6.2 ± 7.4 points per two-year period.69 Age, but not GAA1 
repeat length, was a significant predictor of change in FARS scores, indicating younger 
patients change faster; the relationship between GAA1 repeat length and rate of 
progression may have been confounded by more severely affected patients approaching 
the ceiling for FARS scores.69 How these rates change over longer periods of time or 
depend on frataxin levels remain unclear. Here, we have expanded upon these findings 
and hypothesized that less severely affected patients with lower frataxin levels would 
have slower disease progression as evidenced by a smaller change in FARS score per 
year. To capture an accurate, potentially linear rate of progression, we excluded patients 
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with less than two years of FARS measurements (with fewer than three total visits) to 
reduce variation in disease progression and patients with FARS scores greater than 100 to 
eliminate a possible ceiling effect. We found an overall rate of change in FARS scores of 
2.3 ± 2.5 points per year in patients with frataxin measurements (n=94), similar to the 
previously reported rate (Table 3.2).69 Age was a significant determinant in disease 
progression; of FRDA patients with recorded frataxin measurements, adults progressed 
significantly slower (1.9 ± 2.0 points per year) than children under the age of 18 (3.7 ± 
3.3 points per year, p = 0.003). On their own, frataxin levels did not predict change in 
FARS scores (p = 0.503); however, when using multivariate regression analysis to assess 
the effect of frataxin levels on rate of FARS change with respect to age and sex, we found 
the model to be statistically significant (p = 0.002) with age as the main predictor of 
progression (p < 0.001) and frataxin levels approaching significance (p = 0.095).  
Knowing that frataxin levels remain stable over time is advantageous for certain 
clinical trials where measured frataxin protein is used as an outcome measure. If frataxin 
protein levels change in response to pharmacological intervention, then those changes can 
be attributed to the drug. If the lateral flow immunoassay is sensitive enough to detect 
these changes, then these measurements will be a useful biomarker for response of 
treatment in FRDA patients. Repligen Corporation has been testing RG2833, a class one 
HDAC inhibitor designed to upregulate the frataxin gene, as a potential therapy for 
FRDA, and utilized the dipstick assay to measure changes in frataxin expression in 
response to RG2833 treatment.195 RG2833 induced a dose-dependent increase in frataxin 
mRNA (n=47) and protein levels (n=27) in PBMCs isolated from FRDA patients, with 
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10 µM treatment causing a two-fold increase in expression on average (Figure 3.4A,B). 
PBMC response to treatment did not correlate with GAA1 repeat length, indicating that 
RG2833-induced increases in frataxin protein and mRNA are independent of disease 
severity (Figure 3.4C,D). While these are simply preclinical results that will accompany 
phase I testing in subjects, it still shows that the dipstick assay can detect small changes 
in frataxin protein levels from FRDA cells in response to pharmacological intervention, 
and suggests that this assay may be useful in clinical trials where frataxin protein is an 
outcome measure of interest.  
3.4.3 MAP chemotherapy does not significantly worsen cardiac parameters in FRDA 
We also used the dipstick assay to monitor frataxin levels in a FRDA patient 
receving potentially frataxin-altering treatment for other conditions to determine if our 
assay could detect changes in frataxin protein levels.  
A 19-year-old woman developed balance and gait difficulties at age 9 and was 
subsequently diagnosed with Friedreich ataxia at age 13. She carried GAA repeat lengths 
of 700/1000, and baseline frataxin protein levels in whole blood and buccal cells were 
20.5% of control. Hypertrophic cardiomyopathy, scoliosis of 35 degrees, and pes cavus 
were present at baseline evaluation in 2008. This patient began using a walker at age 16. 
Her initial Friedreich Ataxia Rating Scale (FARS) score was 65.5, corresponding to an 
individual with overt and significant symptomatology, including the need for assistance 
with ambulation. At that time, she was on a supplement-based regimen, including vitamin 
E, alpha lipoic acid, and coenzyme Q10.   
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At the age of 19, this individual presented with right leg pain after a fall. 
Evaluation with X-ray and MRI revealed a lesion of the distal femoral metaphysis on the 
medial side, which was confirmed to be osteosarcoma by bone biopsy. She was treated 
with 8 months of MAP chemotherapy (Table 3.3), which included methotrexate (12 g/m2; 
weeks 4, 5, 9, 10, 15, 16, 20, 21, 24, 25, 28, 29), doxorubicin (37.5 mg/m2; weeks 1, 6, 
12, 17, 22, 26) and cisplatin (60 mg/m2; weeks 1, 6, 12, 17). After initial therapy, her 
primary lesion was removed at week 11. Throughout therapy, she experienced alopecia, 
oral mucosal irritation, neutropenic fevers, and constipation. After therapy, no residual 
tumor was noted. She had no worsening cardiac symptoms, and although her gait was 
altered by removal of a portion of her femur, subjectively she had no increase in her 
neurologic symptomatology. 
As cisplatin therapy may increase frataxin levels in vitro, we followed frataxin 
protein levels over time using both whole blood and cheek swab samples collected during 
the course of treatment to assess any drug-induced increases or decreases in frataxin 
protein levels. Because frataxin levels remained relatively stable in control and Friedreich 
ataxia patient samples over the course of several weeks (Tables A.7 and A.11), any 
changes in frataxin from baseline levels could be attributed to the MAP therapy. Average 
frataxin levels measured from whole blood and buccal cells were significantly lower than 
control (28.57% and 12.48%, respectively, p < 0.001). Frataxin levels in buccal cells at 
the end of the study remained relatively unchanged (Figure 3.5) when compared with 
before chemotherapy (13.3% and 16.8%, respectively), though slight variations were seen 
throughout the study; these may be attributed to drug-induced oral mucosal irritation. In 
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whole blood, frataxin levels increased from approximately 10% of control to over 40% of 
control after Day 50 of treatment and remained elevated through Day 170 (Figure 3.5). 
No whole blood samples were available for frataxin protein analysis after Day 170. 
As frataxin levels in blood are associated with several different cell types 
(platelets, white blood cells, and red blood cells), changes in frataxin levels might simply 
reflect a change in the relative proportion of these cells in blood as caused by her 
treatment. Hematocrit, hemoglobin, and red blood cell count decreased during treatment, 
with an increased red blood cell distribution width above normal limits (Figure 3.6). 
Although white blood cell count decreased slightly, levels remained within the normal 
range. Mean corpuscular volume remained unchanged, while platelet count decreased 
slightly toward the end of 8 months of treatment (R2 = 0.459, p = 0.004), consistent with 
a general thrombocytopenia associated with chemotherapy (Figure 3.7). 
The anthracycline class of antibiotic drugs, including doxorubicin, is associated 
with cardiotoxicity due to reactive oxygen species production, which seems highly likely 
to exacerbate the cardiac deficits already associated with Friedreich ataxia. Cardiac 
parameters, including intraventricular septum thickness, ejection fraction, and left 
ventricular posterior wall thickness, were evaluated before, during, and after treatment 
via echocardiogram to ensure cardiac function did not worsen with MAP therapy (Table 
3.4). Intraventricular septum thickness was not significantly altered before or during 
MAP therapy (p = 0.773). Ejection fraction did not deviate from the normal range during 
treatment, and importantly, did not significantly decrease (p = 0.418). Left ventricular 
posterior wall thickness increased slowly before, during the course of therapy, and after 
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completion (p = 0.012); intraventricular and left ventricular posterior wall thickness were 
both above normal before start of treatment. Thus, during this short follow-up period, 
doxorubicin did not markedly worsen cardiomyopathy in this patient. 
3.4.4 SNP analysis of SIRT6 and SIRT3 in FRDA reveals potential modifiers of the FXN 
gene 
We investigated whether non-synonymous polymorphisms in HDAC genes were 
associated with FRDA disease phenotype and frataxin protein levels. Genomic DNA 
from 458 subjects across multiple sites was genotyped at 46 non-synonymous SNPs in 
HDAC genes (HDAC10, HDAC5, SIRT3, SIRT5, SIRT6), and SNP scores were assigned 
based on mutation status. The Collaborative Clinical Research Network in Friedreich’s 
Ataxia clinical database was used to analyze the association between HDAC gene 
polymorphisms and features of FRDA including age of onset, FARS score, performance 
measures Z2 and Z3, reciprocals of the 9-hole peg test and timed 25-foot walk, and low-
contrast letter acuity vision (Table 3.5). Of the 46 SNPs analyzed, 42 were identical in the 
study population, suggesting a homogenous ethnic background. The SIRT6 
polymorphism rs352493, which results in a Ser46Asn amino acid change found in 
approximately 10-15% of the population, predicted FARS, Z2 and Z3 scores when 
controlling for age, sex, and GAA1 repeat length (p < 0.005). This polymorphism was 
completely linked to a second polymorphism in CREB3L3 (rs352117) that also predicted 
FRDA phenotype. Patients heterozygous for the asparagine residue (carrying the Ser46 
form) have a less severe neurological phenotype than patients homozygous for 
asparagine. No individuals were found to be homozygous for the Ser46 form. The SIRT3 
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polymorphism (rs1045288), which has a minor allele frequency of approximately 20%, 
was slightly associated with age of onset (p < 0.08) and the Z3 composite score (p = 
0.156). The HDAC10 polymorphism (rs34402301) has a minor allele frequency of 
approximately 3% and was minimally associated with FARS scores (p = 0.084), low-
contrast letter acuity vision (p = 0.068), and age of onset (p = 0.1534). While the SIRT3 
and HDAC10 SNPs had slight predictive value for some neurological performance 
measures, only the relationship between the SIRT6 polymorphism rs352493 and disease 
phenotype reached statistical significance. 
We next investigated whether frataxin protein levels correlated with SIRT6 
(rs352493), SIRT3 (rs1045288) or HDAC10 (rs34402301) mutation status to determine a 
possible role for HDAC polymorphisms in modifying frataxin expression as a means to 
alter disease progression. We initially measured frataxin in whole blood from a small 
subset of patients with different SIRT6 mutation status (Figure 3.8A), and found that 
patients heterozygous for the serine residue had higher levels of frataxin protein 
compared to those homozygous for asparagines (mean 36.4%, 29.4% of control, 
respectively). While not statistically significant (p = 0.365), this trend supports our earlier 
findings of Ser46 predicting less severe phenotype, and the results appeared encouraging; 
however, this was a preliminary study with a small number of patients, and we did not 
have clinical information on these individuals to determine whether frataxin levels were 
influenced by GAA repeat length. We expanded our study to measure frataxin levels in 
buccal cells and whole blood from over one hundred patients with known SIRT6 mutation 
status to investigate whether a similar trend held for a more meaningful sample size 
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(Figure 3.8B,C). Similar to our preliminary studies, frataxin levels measured from buccal 
cells and whole blood were higher in the S/N group (25.2% and 36.3% of control, 
respectively) compared to the N/N group (20.9% and 29.5% of control, respectively), but 
these differences were not statistically significant (p = 0.249 and 0.167, respectively). 
When including GAA1 repeat length, age and sex to correct for clinical differences 
between the two groups, the regression model becomes statistically significant in both 
buccal cells and whole blood (p < 0.001); however, this significance was driven mainly 
by GAA1 repeat length (p < 0.001), and not SIRT6 mutation status (p =  0.060 and 0.604, 
respectively). Patients in the S/N group did have a higher mean age of onset than the N/N 
group (17.0 vs 13.4), and the difference was statistically significant (p = 0.026), which 
may account for some of the trend in frataxin levels. Predictably, patients in the S/N 
group also had a shorter mean GAA repeat length on the shorter allele than the N/N 
group (620.8 vs 556.7), but these differences were also not significant (p = 0.122). 
We also measured frataxin levels by mutation status in HDAC10 (rs34402301) 
and SIRT3 (rs1045288) SNPs; however, no significant differences in frataxin levels were 
predicted based on mutation status in buccal cells or whole blood for either gene (Figure 
3.9A-D). When accounting for GAA1 repeat length, age, and sex, the regression models 
assessing predictive value of SIRT3 mutation status on frataxin levels were significant for 
in buccal cells and whole blood, but significance was again driven mainly by GAA1 
repeat length and not SIRT3 mutation status (p = 0.554 and 0.705, respectively). 
Similarly, while the regression model was significant, the rs34402301 SNP in HDAC10 
does not appear to predict frataxin levels in buccal cells or whole blood when including 
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GAA1 repeat length, age, and sex in the analysis (p = 0.211 and 0.836, respectively). 
Taken together, while polymorphisms in HDAC genes appear to predict neurological 
severity as measured by the FARS exam or other performance measures, these 
differences may not be influenced by changes in measured frataxin protein levels. 
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3.5 Discussion 
3.5.1 Diagnostic utility of immunoassays in patients with atypical Friedreich ataxia 
Our first application of the lateral flow immunoassay was measuring frataxin 
levels in suspected FRDA patients with an atypical genetic composition. We collected 
cheek swab and/or whole blood samples from patients with FRDA-like phenotype and 
zero or one known disease-causing mutation to determine if frataxin protein levels were 
in the low FRDA patient range. In seven out of ten atypical patients, frataxin protein 
levels were reduced, with frataxin levels below 20% of average controls in six of these 
individuals (Table 3.1). DNA from six atypical patients with reduced frataxin levels were 
submitted for MLPA analysis to determine whether there were any deletions present in 
exons of the FXN gene. We found a novel heterozygous partial exon 2/3 deletion in 
atypical patient P.A.001, and a heterozygous exon 5 deletion in atypical patient P.A.005 
(Figure 3.1). Because these individuals had low measured frataxin protein levels, we 
anticipate that these deletions result in an absence of frataxin synthesis or a rapid 
degradation of a mutated form of frataxin, although it may be possible for the deletions to 
eliminate or cover the frataxin epitope. We must also consider the possibility that the 
other four patients testing negative in the MLPA analysis may actually be carriers that 
registered positive for low frataxin in the immunoassay. The carrier frequency for FRDA 
is approximately 1:100, so they could have potentially been in the low range of carrier 
frataxin levels; however, these individuals have a phenotype resembling FRDA, 
suggesting that they more likely have an as yet undetected mutation resulting in disease 
either in the promoter region or in another gene that modifies frataxin expression. 
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P.A.010 had a measured frataxin level of “0%” of control, which means their frataxin 
levels were below the assay’s limit of detection. As complete knockout of frataxin is 
expected to be lethal based on animal models, we can assume P.A.010’s frataxin level to 
be nonzero. 
We also discovered a large discrepancy between frataxin levels in buccal cells and 
whole blood from an atypical patient (P.A.002) with a start codon mutation (2delT) 
inherited from his father on one allele with no other known disease-causing mutations. To 
investigate the source of increased whole blood frataxin in this individual, we 
fractionated whole blood to measure frataxin levels in platelets and the RBC pellet in 
P.A.002 and his family. Surprisingly, the RBC pellet contained elevated frataxin levels 
(Figure 3.2) in P.A.002, his father, and one sibling relative to other cell types, suggesting 
that the start codon mutation results in an increased level of extramitochondrial frataxin 
through an as yet unidentified mechanism. Zhu, et al presented a case of a compound 
heterozygote with a GAA expansion of ~900 repeats on one allele, with the same 2delT 
start codon mutation on the other allele.221 In both cases, the siblings and parents carrying 
the start codon deletion were unaffected. The authors hypothesized that this deletion may 
create an alternate start codon that results in a truncated form of frataxin missing its N-
terminal mitochondrial targeting sequence; however, it was not determined whether this 
form of frataxin was expressed. This hypothesis is consistent with our finding that 
frataxin in the RBC pellet, which contain very few mitochondria, was elevated only in 
individuals carrying the deletion. We still do not know what the second disease-causing 
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mutation is in P.A.002, which may be severe enough to cause a compensatory 
upregulation of frataxin in cells that rapidly turn over. 
The lateral flow immunoassay shows utility as a complementary diagnostic tool, 
and can be used before more invasive or more expensive diagnostic tests are 
administered. However, certain mutations may result in elevations of frataxin in whole 
blood through unknown biochemical mechanisms. These results amplify the importance 
of testing in individuals with any kind of idiopathic ataxia, and for testing in multiple cell 
types to avoid miss diagnosing potential FRDA patients. Taken together, these reports 
indicate that the spectrum of mutations for FRDA is wider than originally anticipated. 
More research must be done to uncover the effect these mutations have on frataxin 
protein structure and function to determine which therapeutic strategy may be most 
beneficial. 
3.5.2 Longitudinal frataxin measurements and response to HDAC inhibitor therapy 
We next determined whether our use of the dipstick assay was sensitive enough to 
detect changes in frataxin protein levels in response to pharmacological intervention, so 
that the assay may show utility in clinical trials where frataxin protein is an outcome 
measure. We first examined frataxin levels over time to determine if there was a basal 
change in FRDA patients; however, we found that frataxin levels remained stable in 
control, carrier, and patient blood samples over a period of up to four years as evidenced 
by low CV values and no significant differences in measurements between patient visits. 
These data suggest that frataxin levels may be set from an early age, and any changes in 
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response to treatment are likely a result of that agent. To determine whether the dipstick 
assay shows utility in measuring changes in response to treatment, Repligen Corporation 
treated PMBCs isolated from FRDA patients with RG2833, a class I HDAC inhibitor 
designed to upregulate frataxin expression.195 While RG2833 successfully induced a 
dose-dependent increase in frataxin mRNA and protein in PBMCs, it is unclear if these 
changes in frataxin levels are clinically meaningful, and the increase in frataxin 
expression is probably associated with increased expression of multiple genes.44 
However, these results show the dipstick assay can detect small changes in frataxin 
protein in peripheral tissues in response to drug treatment, and may show utility in 
clinical trials where change in frataxin protein in an outcome measure of interest. 
FARS scores are often used in clinical studies to assess baseline severity of 
neurological disease and its response to treatment; however, correlation of frataxin levels 
with FARS scores and its rate of change had not yet been thoroughly explored. That 
frataxin levels appeared to be unchanging over time was an interesting result, and we 
investigated whether frataxin levels could predict the severity of disease as measured by 
baseline FARS scores, and rate of disease progression, as measured by the rate of change 
in FARS score per year. If so, frataxin levels could represent a biomarker for not only 
disease severity, but for progression as well. We found that GAA1 (p < 0.001, R2 = 0.441) 
and frataxin levels (p < 0.001, R2 = 0.245) both correlated with baseline FARS scores in a 
linear regression model accounting for patient age and sex, which suggest patients with 
longer GAA repeats and lower frataxin levels have a more severe neurological phenotype 
controlling for age. 
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For examination of disease progression, certain criteria were required for patients 
to be included in analysis to increase the chance that we were actually examining a linear 
rate of change. In our analysis, we included only individuals with more than two years of 
FARS data to reduce overall variation, and excluded those patients with FARS scores less 
than 20 or greater than 100 to reduce confounding floor and ceiling effects of the rating 
scale. We also eliminated patients with potential biochemical confounding 
characteristics, including two patients with G130V and I154F point mutations and one 
LOFA patient with chronic lymphocytic leukemia, which increases WBC count and 
artificially elevates frataxin levels in whole blood relative to cheek swab samples. We 
found an overall rate of FARS change of 2.3 ± 2.5 points per year, similar to the average 
progression of 2.6 points per year seen between year one and two in a previous study 
(Table 3.2).69 This suggests rates of change may be linear after the first two years until 
scores approach the ceiling of the scale. We hypothesized that more severely affected 
patients, those with longer GAA repeats and lower frataxin levels, would show a more 
rapid progression manifested as a larger change in FARS score per year compared to less 
severely affected individuals; we would also expect scores to plateau as they approach 
the ceiling of the scale after several years. Our finding that adult patients progressed 
slower than children under 18 (1.9 ± 2.0 and 3.7 ± 3.3 points per year, respectively) 
seemed to reinforce this theory, as older patients are typically those who develop the 
disease later in life and are less severely affected than children, or are patients who 
developed FRDA early on and have since reached the ceiling of the scale and thus, no 
longer demonstrate rapid progression. We did not find a significant difference in rate of 
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FARS change between males and females (2.2 ± 2.1 and 2.3 ± 2.7, respectively; p = 
0.904). Previous studies following the first two years of progression noted sex differences 
possibly attributed to muscle strength; since we only analyzed patients with two or more 
years of FARS scores, muscle strength may no longer be able to compensate for 
progression of ataxia. Finally, we used multivariate regression analysis to assess the 
effect of frataxin levels on rate of FARS change accounting for age and sex. The model 
was statistically significant (p = 0.002), with age as the main predictor of disease 
progression (p < 0.001) and frataxin levels approaching significance (p = 0.095); 
however, age is complicated by the fact that we don’t see LOFA patients at a young age. 
All young patients are affected individuals; older patients are not only LOFA patients 
presenting with their first symptoms, but patients in their second or third decade of 
disease. As natural history studies progress and more complete clinical data are recorded 
on current and newly diagnosed patients, accuracy of relationships between disease 
parameters will only improve. Early diagnosis of FRDA and consistent monitoring of 
disease progression through measurement of FARS scores and frataxin levels is vital for 
accurately assessing disease progression, both naturally and in response to 
pharmacological intervention. While many clinical trials point to a decrease in absolute 
FARS scores as a sign of improvement in response to treatment, it may now be possible 
to conduct long-term studies to determine whether agents that increase frataxin levels 
also affect predicted rate of progression. 
In this section, we have not only shown that measured frataxin levels appear to be 
relatively stable over time, but that the lateral flow immunoassay can be used to detect 
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changes in frataxin levels in response to pharmacological intervention. Frataxin levels 
from whole blood also correlate strongly with baseline FARS scores and rate of change in 
FARS scores when accounting for patient age. Taken together, frataxin measurements 
from whole blood may be a useful biomarker for assessing disease severity and 
progression in FRDA patients. This is useful not only for natural history studies, but in 
clinical trials where treatments aimed to increase frataxin levels are investigated for their 
properties to reduce progression of disease. 
3.5.3 MAP Chemotherapy and FRDA 
In this chapter, we also followed an individual with FRDA undergoing 
chemotherapy for osteosarcoma and measured frataxin protein levels from whole blood 
and cheek swab samples during the course of 8 months of treatment. Since the 1980s, 
most treatment regimens for osteosarcoma have consisted of a combination of 
methotrexate, doxorubicin, and cisplatin, referred to as MAP chemotherapy.92 Cisplatin is 
a cancer chemotherapeutic agent that induces apoptosis through formation of platinum-
DNA adducts that inhibit DNA replication and transcription.219 Cisplatin may also induce 
frataxin expression in ovarian carcinoma cell-lines through promotion of defense 
mechanisms against reactive oxygen species-induced damage.78 While these agents are 
vital for treatment of osteosarcoma, it remained unclear as to what effects the 
chemotherapy would have on FRDA disease state and frataxin protein levels, in 
particular. In this patient, frataxin protein levels in buccal cells are similar pre- and post-
treatment, with any fluctuations likely associated with therapy-induced oral mucositis. 
Frataxin protein levels in whole blood appeared to increase after Day 50 of treatment. 
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This is potentially consistent with the studies in cell lines, but the exact cause of elevated 
frataxin levels is unclear. These changes could be a result of drug-induced frataxin 
increase, but also could represent possible selection for blood cells containing higher 
levels of frataxin, either by selecting cells with shorter GAA repeats or by changing the 
maturational state of circulating blood cells. Still, the data clearly show that MAP 
chemotherapy does not suppress frataxin synthesis further than at baseline. 
 Doxorubicin (adriamycin), another component of MAP chemotherapy, is a 
member of the anthracycline class of antibiotics that exerts its cytotoxic effects through 
intercalation of DNA, interfering with replication and slowing proliferation of tumor 
cells.9,133 Cardiac toxicity after treatment for osteosarcoma is exclusively caused by 
doxorubicin, potentially through increased free radical production and oxidative stress.92 
Since cardiac hypertrophy and an increased sensitivity to oxidative stress are already 
hallmarks of FRDA, doxorubicin treatment could potentially exacerbate disease 
progression. One of the agents in trials for therapy of cardiomyopathy in FRDA, 
deferiprone, is protective against doxorubicin-induced cardiotoxicity in animals, 
suggesting a link between the mechanisms of FRDA and doxorubicin cardiomyopathy. 
However, there was no systematic loss of cardiac function or significant hypertrophy in 
this subject, allaying fears that FRDA and doxorubicin may synergistically cause 
progressive cardiac disease. While already outside the normal range, intraventricular 
septum thickness did not significantly change during treatment. Left ventricular posterior 
wall thickness increased during treatment; however, the change during treatment was 
similar in magnitude to that of before and after treatment, suggesting normal progression 
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of hypertrophy in FRDA. Mean ejection fraction increased during treatment, but returned 
toward baseline after treatment; importantly, the ejection fraction remained within normal 
range throughout the duration of the study. 
This patient’s family reported that her neurological symptoms improved during 
the treatment course, but formal neurological assessment is confounded by effects of 
disease and by the surgical intervention on her femur. Still, we are able to report that an 
individual with FRDA can undergo MAP chemotherapy without the risks of significantly 
worsened cardiac parameters, neurological deterioration, or further lowering of frataxin 
levels. 
3.5.4 SNP analysis of SIRT6 and SIRT3 in FRDA 
Finally, in this chapter we examined the potential predictive value of sirtuin gene 
polymorphisms on FRDA disease severity and frataxin protein levels. Regression models 
showed that a Ser46Asn polymorphism in SIRT6, in which FRDA patients carry the 
Ser46 residue, predicted a less severe neurological phenotype when controlling for age, 
sex, and GAA1 repeat length; patients heterozygous for the asparagine residue had a less 
severe neurological phenotype than patients homozygous for asparagines as determined 
by multiple neurological parameters, including Z2 and Z3 performance measures, FARS 
scores, and reciprocal-scored 9-hole peg test and timed 25-foot walk. There were minor 
associations approaching significance between SIRT3 polymorphism (rs1045288) and age 
of onset and the Z3 composite score. Similarly, the HDAC10 polymorphism 
(rs34402301) was also minimally associated with FARS scores, low-contrast letter acuity 
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vision, and age of onset, though these relationships were also not statistically significant. 
SIRT3 and HDAC10 SNPs only had slight predictive value for these performance 
measures, and mostly had an impact on nonneurological features (data not shown). Only 
the relationship between the SIRT6 polymorphism rs352493 and disease phenotype 
reached statistical significance.  
Next, we investigated whether mutation status in the above HDAC genes 
predicted frataxin protein levels. When accounting for GAA1 repeat length, age, and sex, 
we found that our regression model to assess the predictive value of SIRT6 mutation 
status on frataxin levels was statistically significant (p < 0.001), suggesting that patients 
with asparagine residues express higher levels of frataxin protein. However, this 
relationship is largely driven by GAA1 repeat length and not mutation status based on p-
values from our regression model. Polymorphisms in SIRT3 and HDAC10 did not 
significantly predict disease phenotype, but there were minimal associations between 
mutation status and a subset of parameters that approached significance, including age of 
onset, Z3 composite scores, FARS scores, and low-contrast letter acuity vision. Our 
regression models to determine whether SIRT3 or HDAC10 polymorphisms predicted 
frataxin levels when accounting for GAA1 repeat length, age, and sex were again 
significant (p < 0.001); however, these relationships were driven largely by GAA1 repeat 
length, and not by frataxin levels (p =  0.705 and 0.836 for SIRT3 and HDAC10 in whole 
blood, respectively). However, even though we now have genotyped 505 patients, we 
have only measured frataxin protein from whole blood in 181 of them. As the minor 
allele frequency of the SNPs of interest occur is between 10-20%, this means we have a 
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small number of measured frataxin levels from patients that carry these mutations in 
SIRT6 (n=20), SIRT3 (heterozygous n=69, homozygous n=14), and HDAC10 (n=22). 
This could result in wider confidence intervals and may not accurately reflect true 
differences between mutation statuses. We will need to collect blood samples for frataxin 
measurements from as many of the remainder of these patients as we can to obtain a 
larger sample size with less variation.  
In summary, while the Ser46Asn polymorphism in SIRT6 leads to a less severe 
neurological phenotype, it may not be heavily influenced by a change in frataxin protein 
levels. Future research will need to examine the effect this polymorphism has on SIRT6 
expression levels and/or function to elucidate the connection between mutation and 
phenotype. In the meantime, the dipstick assay may be useful for detecting differences in 
frataxin levels within a patient population based on difference in mutations or expression 
of other modifiers of the FXN gene, including transcription factors and other cis-acting 
binding elements.45,107,143,156 
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Table 3.1 – Clinical information and frataxin levels of suspected FRDA patients with 
atypical genetic presentation. Patients with low frataxin levels were further analyzed by 
MLPA.
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Figure 3.1 – Multiplex Ligation-Dependent Probe Amplification analysis of FRDA 
patients with suspected atypical genetic composition (Table 3.1) has expanded the 
spectrum of known mutations in the FXN gene, including (A) a heterozygous partial 
exon2/3 deletion in one patient and (B) a heterozygous exon 5 deletion in another FRDA 
patient. SETX and APTX are genes involved in ataxia-ocular apraxia, and were used as a 
control for FRDA. 
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Figure 3.2 – Frataxin analysis of the family of an atypical FRDA patient with a start 
codon mutation (2delT) on one allele, and an unknown mutation on the other. (A) The 
lateral flow immunoassay was used to measure frataxin from buccal cells, whole blood, 
RBC pellets, and platelets of the atypical patient, his family, and representative controls 
(n=3). (B) Whole blood and RBC pellet frataxin levels are elevated in the atypical 
patient, his father, and one sibling relative to platelet and cheek swab frataxin levels. 
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Figure 3.3 – Short-term stability of whole blood frataxin levels in FRDA patients (n=31). 
Frataxin levels were measured at baseline (0 weeks), 2 weeks, and 4 weeks. (A) Age of 
onset correlated strongly with GAA1 repeat length in our patient cohort (R2 = 0.794, p < 
0.001). Frataxin levels also correlated with age of onset (R2 = 0.385, p < 0.001) and 
GAA1 repeat length (R2 = 0.583, p < 0.001). (B) FRDA patient frataxin levels remained 
stable over four weeks, showing no statistical differences between 0 and 2 weeks (p = 
0.892), 2 and 4 weeks (p = 0.191), and 0 and 4 weeks (0.257). 
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Table 3.2 – Baseline FARS scores and rate of neurological progression measured in 
FRDA patients. Patients were included only if they had more than two years of FARS 
data, and excluded if FARS scores were less than 20 or greater than 100 to reduce 
confounding floor and ceiling effects of the rating scale. Patients with potential 
biochemical confounding characteristics were also excluded. FARS: Friedreich ataxia 
rating scale.
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Figure 3.4 – Dose-dependent effect of HDAC inhibitor RG2833 on frataxin mRNA and 
protein levels in PBMCs isolated from FRDA patients. (A) FRDA PBMCs (n=47) show a 
dose-dependent increase in average frataxin mRNA and (B) frataxin protein expression 
(n=27). Error bars represent standard deviation. (C,D) Fold change of mRNA and protein 
did not correlate with GAA1 repeat length, suggesting frataxin increases were 
independent of disease severity. This figure was adapted from experiments performed by 
Repligen Inc. 
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Table 3.3 – MAP chemotherapy treatment schedule; Week 1 marks period that first 
treatment was received. Drugs were administered in sodium chloride 0.9% IV 
(doxorubicin) or IVPB (cisplatin). High-dose methotrexate was followed by leucovorin 
rescue to minimize methotrexate toxicity 
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Figure 3.5 – Frataxin levels in cheek swabs and whole blood isolated from a FRDA 
patient with osteosarcoma during and after treatment with MAP chemotherapy. Day 1 
marks first treatment. 
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Figure 3.6 – Blood composition of a FRDA with osteosarcoma before and during MAP 
chemotherapy. Day 1 marks first treatment. WBC: white blood cells, RBC: red blood 
cells. 
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Figure 3.7 - Blood composition of a FRDA with osteosarcoma before and during MAP 
chemotherapy. Day 1 marks first treatment.
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Table 3.4 – Cardiac parameters before, during, and after MAP chemotherapy. Day 1 
marks day that first treatment was received. IVS: intraventricular septum thickness, EF: 
Ejection Fraction, LVPW: left ventricular posterior wall thickness; Measurements made 
at the Kaiser Permanente Medical Center. 
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Table 3.5 – Associations of HDAC gene polymorphisms with parameters of FRDA 
disease progression. Cells are color-coded to represent p-values of less than 0.2 (yellow), 
0.1 (light orange), 0.05 (dark orange), and 0.01 (red). AOO: age of onset, 9HPT: 9-hole 
peg test, T25W: timed 25-foot walk, FARS: Friedreich ataxia rating scale, LCLA: low-
contrast letter acuity. 
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Figure 3.8 – Frataxin boxplots by SIRT6 (rs352493) mutation status in whole blood and 
cheek swab samples. (A) Initial experiments showed increased frataxin in the S/N group 
compared to the N/N group (mean 36.4%, 29.4% of control, respectively; P = 0.365). 
Frataxin levels measured from (B) buccal cells and (C) whole blood were higher in the 
S/N group (25.2% and 36.3% of control, respectively) compared to the N/N group 
(20.9% and 29.5% of control, respectively), but these differences were not statistically 
significant (p = 0.249 and 0.167, respectively). Frataxin levels in buccal cells and whole 
blood were not predicted by SIRT6 mutation status when accounting for GAA1 repeat 
length, age, and sex (p = 0.060 and 0.604, respectively).   
  
107 
 
 
 
 
 
Figure 3.9 - Frataxin boxplots by HDAC10 (rs34402301) and SIRT3 (rs1045288) 
mutation status in whole blood and cheek swab samples. No significant differences in 
frataxin levels were detected between mutation status in whole blood or buccal cells for 
either (A, B) SIRT3 or (C, D) HDAC10.  
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Chapter 4: Investigation of mitochondrial metabolism in Friedreich ataxia 
4.1 Abstract 
 The lack of useful biomarkers of FRDA pathogenesis has hindered the analysis 
and development of effective treatments. A growing body of evidence suggests that 
metabolic dysfunction may contribute to or result from FRDA pathogenesis, yet there is 
no rapid assay to quantify these changes. In this chapter, we used SILEC methodology to 
characterize changes in CoA species in frataxin siRNA knockdown HEK293 cells as well 
as freshly isolated human platelets. We found significant increases in succinyl-
CoA:acetyl-CoA ratios in both HEK293 frataxin knockdown cells and platelets isolated 
from FRDA patients relative to controls. We then performed isotopic labeling with [U-
13C6]-glucose and [U-13C16]-palmitic acid in HEK293 knockdown cells and human 
platelets and fibroblasts to determine relative flux of mitochondrial short-chain acyl-CoA 
metabolites. A decrease in [U-13C6]-glucose-derived acetyl-CoA and an increase in [U-
13C6]-glucose-derived succinyl-CoA was measured in frataxin knockdown HEK293 cells 
compared to scrambled siRNA controls. [U-13C16]-palmitic acid-derived acetyl-CoA was 
increased in frataxin knockdown HEK293 cells and FRDA fibroblasts compared to 
controls, but was decreased relative to controls in FRDA platelets. These experiments 
represent the first time changes in acyl-CoA species were measured in FRDA platelets 
and fibroblasts, and suggest that there is a rearrangement of metabolic pathways in 
unaffected cell types in FRDA. This methodology can be expanded to include a broader 
set of metabolites to further characterize changes in metabolism in FRDA and other 
mitochondrial disorders. By understanding metabolic rearrangement in FRDA, we can 
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develop new biomarkers of disease and potentially uncover novel targets for drug 
development or understand mechanisms of FRDA pathogenesis. 
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4.2 Introduction 
4.2.1 LC/MS and stable isotope labeling overview 
 Liquid chromatography (LC) coupled with tandem mass spectrometry (MS) 
provides a highly sensitive means for separation and measurement in proteomic analyses, 
and is a useful tool for measuring thousands of analytes from  a single biological 
sample.89 Matrix effects on analyte stability, extraction, and ionization efficiency are 
evident in any MS-based measurement of endogenous metabolites, and require the use of 
appropriate internal standards that mimic the physiological and biochemical analytes of 
interest.94,126,155,162 The use of a stable isotope-labeled analog of a compound is an ideal 
internal standard, as it is identical to the compound of interest except for mass; structural 
analogs are undesirable as internal standards, as they exhibit different retention times and 
ionization properties compared to the analyte of interest.39 However, these stable isotopic 
analogs had been difficult to synthesize. Stable isotopic labeling of amino acids in cell 
culture (SILAC) is a method that was developed to generate a library of heavy-labeled 
proteins for use as internal standards.142 In this method, cells are grown in culture media 
in which unlabeled amino acids are replaced with their heavy-labeled form. The labeled 
form of the amino acids are exclusively incorporated into cellular proteins through 
protein synthesis, and result in an almost purely labeled set of proteins after multiple 
passages.142 The cells can be lysed to produce a stable isotope labeled proteome internal 
standard (SILAP), which can be extracted from the cell culture and spiked into 
experimental samples at a known concentration to quantify proteins of interest.77,146 The 
samples are analyzed by MS, and the relative levels of labeled and unlabeled proteins of 
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interest can be distinguished and measured. Recently, the SILAC methodology was 
adapted by Dr. Sanka Basu in Dr. Ian Blair’s lab to synthetically generate a series of 
labeled coenzyme A (CoA) species for detection and quantification of CoA and short-
chain acyl-CoA thioesters through LC/MS analysis.13,14 This technique, stable isotope 
labeling by essential nutrients in cell culture (SILEC), was developed by growing cells in 
culture media with coenzyme A precursor pantothenate replaced by [13C315N1]-
pantothenate to construct a series of heavy-labeled CoA thioesters that can be extracted 
and utilized as LC/MS internal standards for endogenous short-chain acyl-CoA species. 
4.2.2 Applications of SILEC and isotopic labeling in mitochondrial metabolism 
 CoA thioesters are intracellular biomolecules involved in several metabolic 
pathways of the mitochondrion, including the citric acid cycle (acetyl-CoA and succinyl-
CoA), ketogenesis pathway (acetoacetyl-CoA, HMG-CoA), branched chain amino acid 
metabolism, and fatty acid biosynthesis and degradation (short, medium, and long chain 
acyl-CoA species) (Figure 4.1). Changes in these CoA species may be indicative of 
pathological or physiological metabolic dysfunction, and can potentially be used as a 
marker of mitochondrial disease. For example, the mitochondrial complex I inhibitor 
rotenone, used in models of Parkinson’s disease, induced a dose-dependent decrease in 
succinyl-CoA and an increase in β-hydroxybutyryl-CoA in multiple human cell lines.12 
Rotenone also inhibited biosynthesis of [U-13C6]-glucose-derived [13C ]-acetyl-CoA and 
[13C ]-succinyl-CoA in isotopic tracer analysis of SH-SY5Y neuroblastoma cells, 
suggesting compensatory metabolic rearrangement in a model of mitochondrial 
dysfunction.12 
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Metabolic dysfunction and decreased energy capacity likely play a role in several 
mitochondrial disorders, including FRDA. A proteomic study from hearts of frataxin 
knockout mice recently revealed a rearrangement of mitochondrial energy metabolism, 
including decreased expression of components of complex I/II and increased expression 
of enzymes involved in compensatory pathways of branched chain amino acid 
metabolism, pyruvate decarboxylation, ketone body catabolism, and the citric acid 
cycle.201 In addition, gene expression profiles from PBMCs in FRDA patients and 
carriers revealed altered expression of genes involved in lipid metabolism, which may 
represent a compensatory mechanism for energy production when ATP production 
through the ETC is insufficient.44 Interestingly, these changes were detected in the 
absence of a degenerative phenotype, suggesting rearrangements in metabolism are a 
result of reduced frataxin levels, and not massive cell loss. These findings, coupled with 
the observation that tissues most affected in FRDA have high energy demands, indicate 
that FRDA patients are subject to dysfunctional mitochondrial metabolism.  
Like frataxin protein, CoA thioesters are intracellular species, and require 
extraction from affected cells or tissues for biomarker analysis. While frataxin protein is 
ubiquitously expressed, FRDA is a disease that primarily involves cardiomyocytes and 
neurons of the dorsal columns, both of which are located in clinically inaccessible tissues. 
As a result, surrogates that reflect disease state are needed to substitute for pathologically 
affected tissue types. While these surrogate tissues may not exhibit the pathological 
disease phenotype, they must express the analyte of interest and be of easy access for 
repeated sampling. Accessible tissues and cells typically used in FRDA biomarker studies 
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include whole blood, PBMCs, primary lymphocytes and fibroblasts, and buccal cells. 
Total cellular protein extracted from whole blood and buccal cells was used as described 
above for frataxin analysis, but these cell types may not contain enough mitochondria for 
quantitative CoA thioester analysis. Primary fibroblast cultures and platelets isolated 
from whole blood are both extractable mitochondria-containing cell types that can be 
used for baseline LC/MS analysis of CoA species, as well as isotopic tracer LC/MS 
analysis to assess changes in metabolic flux. 
Since aconitase and complex II are ISC-containing enzymes of the citric acid 
cycle that are affected in FRDA, we hypothesized that dysfunctional mitochondrial 
metabolism may occur as exhibited by changes in short-chain acyl-CoA thioester levels 
between control and FRDA samples. In this section, we used SILEC internal standards 
with LC/MS analysis to measure the baseline differences in the CoA profile between 
control and frataxin knockdown HEK293 cells, as well as between platelets isolated from 
control and FRDA subjects. We also utilized isotopic tracer analysis coupled with 
LC/MS to characterize relative differences in metabolic flux in transfected HEK293 cells, 
platelets, and primary fibroblast cultures. 
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4.3 Materials and Methods 
4.3.1 HEK293 cell culture, siRNA knockdown, and isotopic labeling 
HEK293 cells were maintained in low-glucose MEM (GIBCO) supplemented 
with 7.5%/2.5% FBS/HS (Foundation/GIBCO), 1% pen strep (GIBCO), and 200 nM L-
glutamine (GIBCO) at 37°C, 5% CO2
For isotopic labeling in HEK293 cells, culture medium was removed and replaced 
with labeling medium immediately before siRNA transfection. Unlabeled control cells 
were cultured in low-glucose (1 mg/mL) DMEM (GIBCO) supplemented with 15% FBS 
(Foundation), 1% pen strep (GIBCO), and 200 nM L-glutamine (GIBCO) at 37°C, 5% 
CO
. Within 24 hours, when cells had reached 40-50% 
confluency, cells were transfected for 48 hours with frataxin (Ambion, 144470) or 
negative control Silence pre-designed siRNAs (Ambion, Negative Control siRNA #1) 
using Lipofectamine 2000 reagent (Invitrogen) in Opti-MEM (GIBCO). Knockdown 
success was verified by western blot using an antibody directed toward mature frataxin 
protein (Abcam/MitoSciences) as described in Chapter 2, and was expressed as a 
percentage of frataxin in parallel control samples. Prior to solid phase extraction (SPE) 
purification and LC/MS analysis, cells were collected in PBS and spiked with 0.2 mL 
acid extracted SILEC internal standards. 
2. To label glucose, HEK293 cells were grown in the glucose-free DMEM (GIBCO) 
supplemented with 1 mg/mL [U-13C6]-glucose (Sigma-Aldrich), 15% FBS (Foundation), 
1% pen strep (GIBCO), and 200 nM L-glutamine (GIBCO) at 37°C, 5% CO2. For 
analysis of labeled palmitic acid-derived acyl-CoA species, HEK293 cells were cultured 
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in low-glucose (1 mg/mL) DMEM (GIBCO) supplemented with 100 µM [U-13C16]-
palmitic acid (Sigma-Aldrich), 15% FBS (Foundation), 1% pen strep (GIBCO), and 200 
nM L-glutamine (GIBCO) at 37°C, 5% CO2
4.3.2 Platelet isolation and preparation 
. After incubation for 72 hours at 37°C, cells 
were collected in 1 mL PBS (GIBCO) and spun down for 5 min at 13,000 g. Cell pellets 
were resuspended and sonicated in 1 mL of 10% TCA for short-chain acyl-CoA 
extraction or 3:1 acetonitrile (ACN):isopropanol for long-chain acyl-CoA extraction then 
spun down for 5 min at 13,000 g. The supernatant was transferred to a new 
microcentrifuge tube and stored at -80°C until use for acyl-CoA SPE purification and 
LC/MS analysis. 
FRDA patients were recruited by the Friedreich Ataxia Research Alliance 
(FARA) and were seen at the Children’s Hospital of Philadelphia as part of an ongoing, 
multicenter natural history study.  In addition, age-matched volunteers were used as 
controls.  All subjects provided written informed consent before participating in study 
procedures. Blood was collected in 8.5 mL glass ACD Solution A Vacutainer tubes (BD 
Biosciences, REF 364606) and transferred into 15 mL centrifuge tubes. Blood was spun 
at 129 g in a swing bucket centrifuge for 15 min with no brakes. The upper platelet rich 
plasma (PRP) layer was transferred to a fresh tube and spun at 341 g in a swing bucket 
centrifuge for 15 min with no brakes to pellet platelets. Platelets were resuspended and 
sonicated in 1 mL of 10% trichloroacetic acid (TCA) to extract short-chain acyl-CoA 
species, then spun down for 5 min at 13,000 g. The supernatant was transferred to a new 
microcentrifuge tube and stored at -80°C until use for short-chain acyl-CoA analysis. 
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Prior to solid phase extraction (SPE) purification and LC/MS analysis, samples were 
thawed and spiked with 0.2 mL acid extracted SILEC internal standards (Figure 4.2). 
For isotopic labeling of freshly isolated human platelets, blood was collected in 
8.5 mL glass ACD Solution A Vacutainer tubes (BD Biosciences, REF 364606) and 
transferred into 15 mL centrifuge tubes. Stocks of isotopic tracers were added to whole 
blood for final concentrations of 1 mg/mL [U-13C6]-glucose (Sigma-Aldrich) or 100 µM 
[U-13C16]-palmitic acid (Sigma-Aldrich). Samples were inverted to ensure mixing of 
tracer in blood, incubated for 1 hour at 37°C, and platelets were isolated and processed 
for LC/MS analysis as described above (Figure 4.2). 
4.3.3 Human fibroblast cell culture and isotopic labeling 
Control (GM08402) and FRDA (GM03816, GM03665) fibroblast cell lines from 
Coriell Institute for Medical Research were generously donated to us by Dr. Grazia 
Cotticelli and Dr. Rob Wilson. Clinical and demographic information for these 
individuals was obtained from the Coriell Institute (Table A.12). The GM03816 line 
represents a milder FRDA phenotype, with a GAA1 repeat length of 330, and the 
GM03665 line is derived from a more severely affected patient with an earlier onset of 
disease and a GAA1 repeat length of 780. Fibroblasts were maintained in low-glucose 
DMEM (GIBCO) supplemented with 15% FBS (Foundation), 1% pen strep (GIBCO), 
and 200 nM L-glutamine (GIBCO) at 37°C, 5% CO2. Twenty-four hours after human 
fibroblasts were passaged, culture medium was removed and replaced with labeling 
medium and processed as described above for HEK293 cells.  
  
117 
 
4.3.4 Short- and Long-chain acyl-CoA purification 
Extraction of CoA species and LC/MS analysis were performed in the laboratory 
of Dr. Ian Blair. To purify short-chain acyl-CoA species using a vacuum manifold, Oasis 
HLB SPE columns were pre-conditioned with 1 mL methanol and equilibrated with 1 mL 
H2O. The TCA-extracted lysates (supernatants) were loaded to the columns, and washed 
1x with 1 mL H2O. CoA compounds were eluted with 2x 0.5 mL 25 nM ammonium 
acetate in methanol into fresh glass tubes. Samples were dried under N2 and resuspended 
in 50 µL 5% 5-SSA. 
To purify long-chain acyl-CoA species using a vacuum manifold, Sigma Supelco 
2-(2-pyridyl)ethyl silica gel SPE columns were preconditioned with 1 mL 
ACN/isopropanol/H2O/acetic acid (9:3:4:4 v:v:v:v). ACN-extracted lysates were treated 
with 0.25 mL KH2PO4 and spun at 16,000 g. Supernatants were transferred to glass tubes, 
and 0.125 mL glacial acetic acid was added, and acidified extracts were added to each 
column. Columns were washed with 2.5 mL ACN/isopropanol/H2O/acetic acid (9:3:4:4 
v:v:v:v), and samples were eluted with 1 mL 4:1 methanol:250 mM ammonium formate 
into fresh glass tubes. Samples were dried under N2, resuspended in 50 µL 50:50 ACN: 
H2O, then vortexed and sonicated for 5 minutes in a bath sonicator before LC/MS 
analysis. 
4.3.5 LC/MS analysis 
Short-chain acyl-CoA species were separated using a reversed phase Phenomenex 
HPLC Luna C18 column 2.0 x 150 mm, pore size 5 μm (Waters HPLC XBridge C18 
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column 2.0 x 150 mm, pore size 3 μm for long-chain acyl-CoA species) with 5 mM 
ammonium acetate in water as solvent A, 5 mM ammonium acetate in 95/5 
acetonitrile/water (v/v) as solvent B (100% acetonitrile for long-chain acyl-CoA species) 
and 80/20/0.1 (v/v/v) acetonitrile/water/formic acid as Solvent C. Gradient conditions 
were as follows: 2% B for 1.5 min, increased to 25% over 3.5 min (50% for long-chain 
acyl-CoA species), increased to 100% B in 0.5 min and held for 8.5 min, washed with 
100% C for 5 min, before equilibration for 5 min. The flow rate was 200 μL/min. 
Samples were analyzed using an API 4000 triple quadrupole mass spectrometer (Applied 
Biosystems, Foster City, CA) in the positive ESI mode. Samples (10 μL) were injected 
using a Leap CTC autosampler (CTC Analytics, Switzerland) where they were 
maintained at 4°C, and data was analyzed with Analyst 1.4.1 software. The column 
effluent was diverted to the mass spectrometer from 8 min to 22 min and to waste for the 
remainder of the run. The mass spectrometer operating conditions were as follows: ion 
spray voltage (5.0 kV), compressed air as curtain gas (15 psi) and nitrogen as nebulizing 
gas (8 psi), heater (15 psi), and collision-induced dissociation (CID) gas (5 psi). The ESI 
probe temperature was 450°C, the declustering potential was 105 V, the entrance 
potential was 10 V, the collision energy was 45 eV, and the collision exit potential was 
15 V. Transitions (m/z) for precursor → product ions for the LC-SRM/MS analyses were 
as follows: CoASH (768.1 → 261.1), [13C315N1]-CoASH (772.1 → 265.1), acetyl-CoA 
(810.1 → 303.1), [13C315N1]-acetyl-CoA (814.1 → 307.1), propionyl-CoA (824.1 → 
317.1), [13C315N1]-propionyl-CoA (828.1 → 321.1), malonyl-CoA and BHB-CoA (854.1 
→ 347.1), [13C315N1]-malonyl-CoA and [13C315N1]-BHB-CoA (858.1 → 351.1), succinyl-
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CoA (868.1 → 361.1), [13C315N1]-succinyl-CoA (872 → 365.1), HMG-CoA  (912.1 → 
405.1), and [13C315N1]-HMG-CoA (916.1 → 409.1). Isotopomer distribution analysis of 
short chain acyl-CoA species was performed as described previously.12 
4.3.6 Statistical Analysis 
LC/MS data was analyzed with Analyst 1.4.1 software. Concentrations were 
determined from regression lines of standard curves and normalized for protein 
concentration. Statistical analysis was performed using STATA SE 11 software and MS 
Office Excel 2007. Student’s t-test was used to compare mean values between control 
and FRDA cells. 
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4.4 Results 
4.4.1 siRNA knockdown of frataxin in HEK293 cells results in altered acyl-CoA profile 
HEK293 cells were transfected with either frataxin siRNA or a negative control 
scrambled siRNA, and knockdown efficiency was assessed by Western blot analysis. 
After 48 hours, frataxin levels were significantly reduced to approximately ~20% of 
control (Figure 4.3). 
Transfected HEK293 cells were processed for measurement of static levels of 
short-chain acyl-CoAs as described in the Methods section. As the cells were cultured in 
6-well-plates instead of 10 cm dishes, only the most abundant CoA species (CoASH, 
Acetyl-CoA, and succinyl-CoA) could be detected and analyzed by LC/MS. We 
measured a significant decrease (p < 0.05) in the acetyl-CoA:succinyl-CoA ratio in 
frataxin knockdown cells compared to scrambled negative controls (Figure 4.3). 
4.4.2 Acyl-CoA measurements from freshly isolated human platelets  
Since platelets are rich in mitochondria containing CoA thioesters and have 
reduced frataxin levels in FRDA, we hypothesized that freshly isolated platelets could be 
used to screen for baseline differences in CoA profiles. In order to preserve metabolic 
function of platelets, isolation was simplified to a two-step centrifugation process before 
labeling with SILEC standards (Figure 4.2). Platelets from FRDA patients had 
significantly decreased frataxin protein levels (p < 0.001) and increased succinyl-CoA 
levels compared to controls. There was no absolute difference in acetyl-CoA levels 
(Figure 4.4). When normalized to acetyl-CoA levels to control for variations in blood 
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volume and platelet count between individuals, the ratio of acetyl-CoA:succinyl-CoA 
was significantly reduced in FRDA platelets compared to controls (p < 0.05), consistent 
with changes seen in frataxin siRNA-treated HEK293 cells. No differences were noted 
for other short-chain acyl-CoA species. Acetyl-CoA:succinyl-CoA ratios did not correlate 
with frataxin levels or GAA1 repeat length, but showed a significant correlation with 
FRDA patient age (p = 0.024, R2 = 0.416). A regression model to analyze the relationship 
between acetyl-CoA:succinyl-CoA ratios and frataxin in FRDA patients accounting for 
sex and age approached statistical significance (p = 0.075, R2 = 0.559), but the 
relationship was driven largely by age (p = 0.062) and not by frataxin levels (p = 0.893). 
Interestingly, the correlation between age and acetyl-CoA:succinyl-CoA was not 
significant in controls (p = 0.594), suggesting that changes in mitochondrial metabolism 
may be enhanced over time in a reduced frataxin environment; however, the sample size 
will need to be increased to further characterize these relationships. 
4.4.3 Isotopic tracer analysis can assess mitochondrial metabolic flux in control and 
FRDA cells 
The changes in CoA profiles described above only provide a “snapshot” of 
mitochondrial metabolism at any given time, and do not indicate how changes in 
metabolic pathways are occurring. To obtain information about changes in flux of 
metabolism in mitochondria, we used isotopic tracer analysis to measure levels of acyl-
CoA species derived from [U-13C6]-glucose or [U-13C16]-palmitic acid. Transfected 
HEK293 cells were used first to test whether we could detect labeling of short-chain acyl-
CoA species in FRDA cell models. HEK293 cells were transfected with either frataxin 
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siRNA or a negative control scrambled siRNA, and knockdown efficiency was assessed 
by Western blot analysis similar to the above experiment. After 72 hours, frataxin levels 
were significantly reduced to 16.0 ± 2.5% of control in unlabeled cells, 37.8 ± 7.0% of 
control in [U-13C6]-glucose labeled cells, and 58.1 ± 5.0% of control in [U-13C16]-palmitic 
acid labeled cells (Figure 4.5A). To assess metabolic flux, HEK293 cells were labeled 
with 1 mM [U-13C6]-glucose immediately before transfection, and grown in the labeling 
media for 72 hours. We measured a significant decrease in labeled acetyl-CoA (p = 0.03) 
and a significant increase in labeled succinyl-CoA (p = 0.04) in frataxin knockdown cells 
relative to negative controls (Figure 4.5B). The increased succinyl-CoA in frataxin 
knockdown cells is consistent with our results from baseline acyl-CoA measurements 
above, and suggests that either glucose-derived acetyl-CoA is being utilized to produce 
succinyl-CoA, or there is an increase in alternate pathways to generate succinyl-CoA 
such as beta-oxidation of fatty acids or branched chain amino acid catabolism. To 
investigate whether metabolism of fatty acids is altered in a cellular model of FRDA, we 
measured levels of short-chain CoA species derived from [U-13C16]-palmitic acid in 
transfected HEK293 cells. HEK293 cells were labeled with 100 µM [U-13C16]-palmitic 
acid immediately before transfection, and grown in the labeling media for 72 hours.  We 
found a significant increase in [U-13C16]-palmitic acid-derived acetyl-CoA in frataxin 
knockdown cells compared to scrambled siRNA controls (22.0% vs 11.7%, p = 0.02; 
Figure 4.5C). We did not detect significant labeling of other short-chain acyl-CoA 
species by [U-13C16]-palmitic acid. Taken together, these results suggest that frataxin 
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knockdown in HEK293 cells results in a potential compensatory shift in mitochondrial 
metabolism towards increased fatty acid oxidation. 
We next examined the steady-state differences in acyl-CoA levels between 
controls and FRDA patient samples. We initially used platelets as they represent easily 
extracted, mitochondria-rich cells that demonstrate altered metabolism in response to the 
complex I inhibitor rotenone [Basu 2012, unpublished]. To validate labeling of CoA 
species in platelets, we treated whole blood drawn from controls with [U-13C6]-glucose 
and [U-13C16]-palmitic acid for 1 hr at 37°C, and measured the percentage labeling of 
short-chain acyl-CoA species (Figure 4.6A). Neither low (1 mg/mL) nor high (4.5 
mg/mL, data not shown) concentrations of [U-13C6]-glucose resulted in significant 
labeling over untreated controls, while 100µM [U-13C16]-palmitic acid resulted in 
approximately 10-25% of short-chain CoA species, suggesting platelets may rely more 
heavily on fatty acid oxidation than glycolytic catabolism of glucose to generate actyl-
CoA. We next compared metabolism between control and FRDA platelets (n=6) by 
measuring isotopic labeling of short-chain acyl-CoAs derived from a 100µM [U-13C16]-
palmitic acid. Frataxin protein was significantly reduced in FRDA platelets relative to 
control (36.5 ± 2.9% of control) as measured by dipstick assay (Figure 4.6B). There were 
significant decreases in labeling of succinyl-CoA in M2 (p = 0.01) and 3-HMG-CoA in 
M2 (p = 0.03) and M4 (p = 0.004), with a nonsignificant decrease in acetyl-CoA labeling 
in M2 in FRDA platelets relative to control (Figure 4.6C). No labeling of CoASH in 
either control or FRDA platelets was seen, signifying the labeling was not a result of 
[13C] incorporation into the CoA moiety. There was no relationship between patient 
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frataxin levels, age of onset, or GAA1 repeat length and level of acyl-CoA labeling, 
which may be attributed to the small sample size and/or homogeneity of clinical features 
amongst the six patients (Table A.13). Taken together, these results suggest an inability 
for platelets to take up or metabolize glucose, with a potential deficiency in fatty acid 
metabolism in FRDA platelets. While platelets appear to demonstrate utility for 
assessment of fatty acid metabolism, we were unable to detect any [U-13C6]-glucose-
derived short-chain acyl-CoA species, which may indicate that different cell types rely on 
different metabolic pathways. 
We moved into patient and control fibroblasts obtained from the Coriell Institute 
for short-chain acyl-CoA isotopomer analysis derived from [U-13C6]-glucose. We initially 
performed a time-course experiment with 1 mg/mL [U-13C6]-glucose in fibroblast culture 
media to determine an optimal time before labeling of acetyl-CoA reached a plateau 
(Figure 4.7A). We found that approximately 21.4% of acetyl-CoA was labeled (M2) in 
control fibroblasts at 48 hours and 24.6% after 72 hours, demonstrating a decreased rate 
of isotopic enrichment between 48 and 72 hours (Figure 4.7A). Similarly, approximately 
17.7% of acetyl-CoA was labeled (M2) in FRDA fibroblasts at 48 hours and 19.8% after 
72 hours, also showing a decreased rate of isotopic enrichment between 48 and 72 hours 
(Figure 4.7A). These data suggest that labeling fibroblasts in the presence of an isotopic 
tracer for 48-72 hours would be sufficient for steady state labeling of target short-chain 
acyl-CoA species without noticeable toxicity. We then measured the percentage of [U-
13C6]-glucose-derived acetyl-CoA (M2) in one control and two FRDA fibroblast cell lines 
at 72 hours to assess whether there were any significant changes in metabolism of 
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glucose to acetyl-CoA in a FRDA model (Figure 4.7C).  Both control and FRDA 
fibroblasts showed approximately ~15% of acetyl-CoA labeled as M2, with no significant 
differences in labeling between the control line (GM08402) and a moderately affected 
FRDA patient (GM03816, p = 0.894) or a more severely affected patient (GM03665, p = 
0.639) (Figure 4.7C). We were unable to detect significant labeling of any other short-
chain acyl-CoA species derived from [U-13C6]-glucose in fibroblasts. Next, we cultured 
control and FRDA fibroblasts in the presence of [U-13C16]-palmitic acid for isotopomer 
analysis to determine if there were significant differences in fatty acid metabolism 
between controls and patients. Similar to [U-13C6]-glucose, we performed a time-course 
experiment with 100 µM [U-13C16]-palmitic acid in fibroblast culture media to 
approximate an optimal time for incorporation of the 13C label into acetyl-CoA, and 
found that sufficient labeling was seen after 72 hours (Figure 4.7B). There was a 
significant increase in [U-13C16]-palmitic acid-derived acetyl-CoA in the FRDA 
GM03665 fibroblast line compared to control GM08402 fibroblasts (45.9% vs 27.6%, p 
= 0.004), suggesting fatty acid oxidation is increased in FRDA fibroblasts in response to 
low levels of frataxin protein (Figure 4.7D). 
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4.5 Discussion 
 In this chapter, we used SILEC internal standards and LC/MS to measure the 
short-chain acyl-CoA profile in transfected HEK293 cells, platelets isolated from FRDA 
patients and control subjects, and primary FRDA and control fibroblast cell lines. As 
mitochondrial dysfunction is believed to play a role in FRDA pathogenesis, we 
hypothesized that there would be significant changes in metabolism, as detected by short-
chain acyl-CoA levels normalized to SILEC internal standards, between patients and 
controls to potentially compensate for any deficiencies in mitochondrial energy 
metabolism. 
Our focus was on succinyl-CoA and acetyl-CoA, two abundant acyl-CoA species 
that are easily analyzed by LC/MS, and are key metabolites in major pathways in 
mitochondria. Glycolysis/pyruvate decarboxylation and fatty acid oxidation are two 
major sources of acetyl-CoA, which then enters the citric acid cycle and is consumed for 
energy production. Succinyl-CoA is an intermediate in the citric acid cycle formed by 
decarboxylation of α-ketoglutarate by α-ketoglutarate dehydrogenase, and is converted to 
succinate by succinate thiokinase. Succinyl-CoA can also be formed from carboxylation 
and rearrangement of proprionyl-CoA, an end product of odd-chain fatty acid oxidation. 
Activities of the ISC-containing enzymes aconitase and succinate dehydrogenase are 
reduced in some tissues in FRDA, which may in turn alter levels of intermediates in the 
citric acid cycle.22,167 Since succinyl-CoA is downstream of aconitase in the citrate acid 
cycle, we hypothesized that energy production through the citric acid cycle would be 
impaired and baseline succinyl-CoA levels would be decreased in FRDA samples relative 
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to controls, similar to rotenone-mediated changes in multiple human cell lines.12 
Surprisingly, we found the opposite: a significant decrease in acetyl-CoA:succinyl-CoA 
ratios in FRDA platelets relative to controls resulting mainly from an increase in 
succinyl-CoA, which was supported by similar in vitro findings in transfected HEK293 
cells. While the exact mechanism behind these changes in acyl-CoA profiles is unclear, it 
may involve rearrangement of compensatory pathways to overcome deficiencies in the 
citric acid cycle.201 This compensation may involve increases in citric acid cycle enzyme 
gene expression, odd-chained fatty acid oxidation or α-ketoglutarate production through 
anaplerotic pathways to bypass deficiencies in aconitase.118,127 On the other hand, a 
buildup of succinyl-CoA could be the result of decreased conversion to succinate, 
suggesting further impairment of the citric acid cycle downstream of succinyl-CoA, 
which may be partially attributed to decreased enzyme activity of succinate 
dehydrogenase.22 Although platelets are clinically unaffected in FRDA, we still see 
reduced frataxin levels and changes in CoA profiles. Though we did not see significant 
correlations between acetyl-CoA:succinyl-CoA ratios and frataxin levels or GAA1 repeat 
length, we did find a strong correlation between acetyl-CoA:succinyl-CoA ratios and age 
of FRDA patients. A regression model investigating frataxin, age, and sex as predictors 
for acetyl-CoA:succinyl-CoA ratios approached statistical significance, with age 
appearing to be the main contributor to the relationship. In controls, the correlation 
between age and acetyl-CoA:succinyl-CoA was not significant; this result is potentially 
interesting, suggesting that age itself is a stressor that can bring out changes in acyl-CoA 
levels in cells with reduced frataxin protein. However, we must also consider our small 
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sample size when drawing conclusions from these early studies. Taken together, these 
findings support the notion that there are underlying global mitochondrial impairments in 
FRDA; however, some cell types are less susceptible than others to their 
pathophysiological effects.186,201 An ex vivo challenge, such as applied oxidative stress or 
a galactose-only environment to drive OXPHOS-dependent ATP production, may be 
required to reveal the phenotype in these tissues.  
It is important to note that these acyl-CoA changes are only static measurements 
of metabolite levels, and do not give us any information on which pathways are 
upregulated or downregulated to cause these changes. To determine the source of 
increased succinyl-CoA, we used isotopic tracer analysis with [U-13C6]-glucose and [U-
13C16]-palmitic acid to measure not only changes in concentrations of metabolites, but 
also flux of metabolism through the citric acid cycle and β-oxidation of long-chain acyl-
CoAs. Evidence for utility of isotopic tracer analysis as a potential biomarker for 
mitochondrial dysfunction in FRDA was shown through experiments highlighting a 
different form of mitochondrial impairment; rotenone-treated SH-SY5Y neuroblastoma 
cells led to inhibition of biosynthesis of [U-13C6]-glucose-derived [13C]-acetyl-CoA and 
[13C]-succinyl-CoA and increased [U-13C16]-palmitic acid-derived [13C]-acetyl-CoA, 
suggesting that isotopic tracer analysis may be a useful marker of altered metabolism in 
disease with mitochondrial dysfunction.12 To assess potential changes in mitochondrial 
metabolism in FRDA, we first performed isotopomer analysis of short-chain acyl-CoAs 
derived from [U-13C6]-glucose and [U-13C16]-palmitic acid in transfected HEK293 cells. 
We found a significant decrease in [U-13C6]-glucose-derived succinyl-CoA and a 
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significant increase in [U-13C16]-palmitic acid-derived acetyl-CoA in frataxin 
knockdowns, which may suggest that decreased glucose metabolism through the TCA 
cycle may be compensated by increased fatty acid oxidation FRDA cells. Interestingly, 
frataxin levels were higher in knockdown cells grown in the added [U-13C16]-palmitic 
acid label compared to cells grown in 1 mg/mL [U-13C6]-glucose and unlabeled 
knockdowns. As fatty acid metabolism appears to be upregulated in frataxin-deficient 
cells, it is possible that these cells benefit from exogenous palmitic acid; however, a more 
likely interpretation is that palmitic acid may be interfering with the lipid-based 
transfection in some manner, affecting transfection efficiency of siRNAs. Frataxin 
knockdowns in the presence of unlabeled palmitic acid were not performed for these 
experiments, but would provide added insight into these findings. 
In platelets isolated from freshly drawn whole blood, we measured significant 
decreases in [U-13C16]-palmitic acid-derived labeling of succinyl-CoA in M2 and 3-
HMG-CoA in M2 and M4, with a nonsignificant decrease in acetyl-CoA labeling in M2 
in FRDA platelets relative to controls. These data suggest that FRDA patients may have a 
decreased dependency of fatty acid oxidation or an impairment in the enzymes required 
for beta-oxidation. As platelets do not have the genetic machinery to upregulate 
expression of enzymes involved in fatty acid oxidation, these changes may be attributed 
to impaired activity of enzymes downstream of reduced frataxin. In fact, fatty acid 
oxidation is dependent on ISC-containing enzymes, which may be affected in FRDA 
patients. The first step of fatty oxidation involves acyl-CoA dehydrogenase, which 
catalyzes the formation of a trans-double bond between C2 and C3 of an acyl-CoA 
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substrate. Acyl-CoA dehydrogenase requires flavin adenine dinucleotide (FAD) as a 
cofactor in the reaction, which is reduced to FADH2. Acyl-CoA dehydrogenase is then 
reoxidized through a reduction of electron-transfer flavoprotein (ETF), which is itself 
reoxidized by ETF:ubiquinone oxidoreductase, an ISC-containing enzyme, which may 
account for the apparent decreased fatty acid oxidation in FRDA patients. 
ETF:ubiquinone oxidoreductase also links fatty acid oxidation to the electron transport 
chain through the reduction of ubiquinone (coenzyme Q) to ubiquinol. During our 
studies, we also tried extracting medium and long-chain acyl-CoA species after labeling 
with [U-13C16]-palmitic acid to measure levels of a wider variety of metabolites of fatty 
acid beta-oxidation; however, we were unable to clearly detect these compounds and will 
need to refine the extraction process before continuing. We had measured an overall 
increase in static levels of succinyl-CoA in FRDA platelets relative to control, so the 
decrease in [U-13C16]-palmitic acid-derived succinyl-CoA is an interesting finding. It is 
possible that platelets from FRDA patients do not rely as heavily on fatty acid 
metabolism compared to controls, and compensate using other pathways that generate 
succinyl-CoA as an intermediate.  Labeling with [U-13C6]-glucose or [13C515N2]-
glutamine did not result in significant labeling of short-chain acyl-CoA species in control 
or FRDA platelets (data not shown), suggesting that platelets either do not rely on 
pathways involving these metabolites, or do not possess mechanisms to take up the 
isotopic tracers.  
In these experiments, we spiked whole blood with isotopic tracers at 
concentrations compatible with normal serum levels of the unlabeled nutrient. This 
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allowed us to detect significant levels of labeled acyl-CoA species without the tracers 
interfering significantly with normal physiological function. However, if levels of 
engodenous, unlabeled compounds are elevated (from diet, for example), then there could 
be unexpected competition with the labeled tracers, dampening the amount of labeling we 
are able to detect. Ideally, subjects were fasted before donation of blood for platelet 
isolation to circumvent this issue, but it was not always possible. Another measure to 
lessen the impact of endogenous compounds on their heavy-labeled isotopes would be to 
spike the compound after platelets are pelleted and washed, instead of before; however, 
preliminary experiments showed that there was no difference in percentage labeling of 
acyl-CoAs when spiking tracers into samples at various stages of processing. In fact, we 
opted to spike tracers into whole blood before isolating platelets, thereby omitting several 
wash steps to decrease harvesting and processing artifacts and maintaining more 
physiologically relevant conditions. 
Finally, we also performed isotopmer analysis of short-chain acyl-CoA species in 
control and patient fibroblasts. While not as rich in mitochondria as platelets, fibroblasts 
represent a relatively easy to obtain source of sample material that can be subjected to 
longer incubation times with isotopic tracers for optimization of labeling. We found that 
culturing fibroblasts in the presence of 13C isotopic tracers for 48-72 hours was optimal 
for labeling of short-chain acyl-CoA species. We found that approximately 20% of total 
acetyl-CoA was labeled in M2 by [U-13C6]-glucose for both control and FRDA 
fibroblasts, without any significant labeling of succinyl-CoA. There was more substantial 
labeling of acetyl-CoA in M2 by [U-13C16]-palmitic acid; FRDA fibroblasts showed 
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significantly higher labeling of acetyl-CoA relative to controls (45.9% vs 27.6%, p = 
0.004). This follows the same trend as transfected HEK293 cells, and suggests that these 
cell types are able to upregulate fatty acid oxidation in a reduced frataxin environment, 
unlike platelets. The GM03665 FRDA fibroblast cell line also appears to grow much 
more slowly than the control GM08402 cell line; the FRDA fibroblasts may be 
upregulating metabolic pathways simply to maintain cell viability. However, we do not 
see a significant difference in [U-13C6]-glucose metabolism between the control and 
patient fibroblast lines when compared to transfected HEK293 cells. This could be 
partially attributed to a selection for cells with higher frataxin levels and a less severe 
phenotype to survive after numerous passages, resulting in an overall homogenization of 
phenotype between cell lines. For example, while frataxin protein levels as measured by 
Western blot and dipstick assay are reduced in the two patient lines relative to the control 
line, there was much variability and the results were difficult to reproduce. Similarly, it 
was reported by the Wilson lab that qRT-PCR analysis of the GM08402, GM03665, and 
GM03816 fibroblasts lines revealed that expression levels of frataxin mRNA were 
indistinguishable (data not shown). To circumvent the possibility that these cell lines may 
no longer carry a relevant phenotype, we can use fibroblasts cultured from skin biopsies 
donated by FRDA patients and healthy controls. While it takes several weeks for cells to 
grow from the biopsy explants, we have already successfully cultured fibroblasts from 
control and carrier skin biopsies in the lab, so we will be able to pursue this option further 
if necessary. 
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In summary, we have shown stable isotope dilution using SILEC internal 
standards in combination with LC/MS can detect changes in acyl-CoA profiles from 
surrogate tissues between FRDA patients and controls. We also show that platelets are a 
plentiful source of metabolically active patient material for isotopic tracer analysis, which 
may lead to advancements in diagnosis and screening of mitochondrial disorders 
involving enzyme deficiencies. Primary fibroblasts or lymphocytes from FRDA patients 
may also be a viable alternative to freshly isolated platelets, as they can be cultured in the 
presence of isotopic tracers for longer periods of time and may show acyl-CoA labeling 
with more compounds than platelets. This isotopomer analysis can be expanded to 
include a multitude of different isotopic tracers for the assessment of metabolic changes 
in any mitochondrial disorder, not just FRDA. For example, we can use [13C6]-leucine, 
[13C6]-isoleucine, or [13C5]-valine to assess metabolism through the TCA cycle from 
branched chain amino acid metabolism, or [13C515N]-glutamic acid for entry into the TCA 
cycle through α-ketoglutarate, which will give us multiple ways to characterize metabolic 
flux through these pathways. In the future, this methodology may potentially elucidate 
downstream changes in metabolism and uncover novel characteristic biomarkers or 
therapeutic strategies aimed at metabolism for FRDA and other diseases affecting 
mitochondrial function. 
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Figure 4.1 – Schematic of the citric acid cycle, including enzymes affected in FRDA, 
measureable short-chain acyl-CoAs, and potential 13C-labeled isotropic tracers for 
measurement of metabolic flux. 
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Figure 4.2 – Isolation and preparation of freshly isolated human platelets for (A) static 
acyl-CoA measurements and (B) isotopic tracer analysis. SILEC: stable isotope labeling 
by essential nutrients in cell culture, SPE: solid phase extraction. 
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Figure 4.3 – Short-chain acyl-CoA measurements in HEK293 cells transfected with 
frataxin siRNA. (A) Frataxin siRNA knockdown resulted in ~80% knockdown (p < 
0.005). (B) Intracellular molar ratios of acetyl-CoA:succinyl-CoA in frataxin knockdown 
and control HEK293 cells. Error bars represent standard deviation (n=3). 
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Figure 4.4 – Short-chain acyl-CoA measurements in freshly isolated human platelets. (A) 
Frataxin levels were significantly lower in patient platelets than controls as measured by 
lateral flow immunoassay. (B) There were no significant differences in total acetyl-CoA 
or succinyl-CoA levels between FRDA patients and controls; however, significant 
differences were seen in the molar ratios of acetyl-CoA:succinyl-CoA and succinyl-
CoA:acetyl-CoA (C). Error bars represent standard error of the mean. 
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Figure 4.5 – Isotopic tracer analysis in HEK293 cells transfected with frataxin siRNA. 
(A) Frataxin siRNA knockdown resulted in significant knockdown under all three 
labeling conditions. (B) We found a significant decrease in [U-13C6]-glucose-derived 
acetyl-CoA (p = 0.03) and a significant increase in [U-13C6]-glucose-derived succinyl-
CoA (p = 0.04) in HEK293 cells transfected with frataxin siRNA. (C) We found a 
significant increase in [U-13C16]-palmitic acid-derived acetyl-CoA (p = 0.02) in frataxin 
knockdown HEK293 cells. Error bars represent standard deviation (n=3). 
  
139 
 
 
Figure 4.6 – Isotopic tracer analysis in platelet isolated from whole blood. (A) Validation 
of short-chain acyl-CoA labeling by [U-13C6]-glucose and [U-13C16]-palmitic acid in 
control platelets (n=3). Neither low (1 mg/mL) nor high (4.5 mg/mL, data not shown) 
concentrations of [U-13C6]-glucose resulted in significant labeling over untreated 
controls, while 100µM [U-13C16]-palmitic acid labeled upwards of 25% of short-chain 
CoA species. (B) Frataxin levels as measured by dipstick assay showed a significant 
decrease in FRDA platelets (36.5% of control, p < 0.001). (C) There were significant 
decreases in labeling of succinyl-CoA in M2 (p = 0.01) and 3-HMG-CoA in M2 (p = 
0.03) and M4 (p = 0.004) in FRDA platelets relative to control. Error bars represent 
standard deviation (A) or standard error of the mean (B,C).
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Figure 4.7 – Analysis of [U-13C6]-glucose and [U-13C16]-palmitic acid labeling of acetyl-
CoA in FRDA and control fibroblast cell lines. (A,B) A time-course study was performed 
with 1 mg/mL [U-13C6]-glucose and 100µM [U-13C16]-palmitic acid in control and FRDA 
fibroblasts to determine the optimal length of time for acetyl-CoA (M2) labeling with 13C 
isotopic tracers. (C) We found that approximately 15% of acetyl-CoA was labeled after 
growing the presence of [U-13C6]-glucose for 72 hours; however, no significant 
differences in labeling were seen between control and FRDA fibroblasts. (D) We found a 
significant increase in [U-13C16]-palmitic acid-derived acetyl-CoA (p = 0.005) in 
GM03665 FRDA fibroblasts. Error bars represent standard deviation (n=3). 
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Chapter 5: Conclusions and Future Directions 
5.1 Conclusions 
In this thesis, we measured biomarkers of Friedreich ataxia to assess severity and 
progression of disease, response to treatment, and mitochondrial dysfunction. We first 
used two different immunoassays for the measurement of frataxin protein from peripheral 
tissues as a screening and potential diagnostic tool in FRDA patients. Using these 
methods, we were able to bypass isolation of mitochondria and measure frataxin protein 
directly from easily extracted tissue samples. We detected significant differences between 
control, carrier, and FRDA patient frataxin levels from a variety of peripheral cell types, 
including PBMCs, platelets, whole blood, and buccal cells. Frataxin levels correlate with 
GAA1 repeat length and age of onset, which suggests frataxin measurements by dipstick 
assay may be a suitable biomarker for severity of disease. Receiver operator curve 
analysis revealed that frataxin measurements from both whole blood and buccal cell 
extracts were useful for screening for carriers and FRDA patients, and that PPV and false 
negative rate was more favorable in whole blood. Lastly, we compared the utility of 
frataxin measurements by the dipstick assay in whole blood to those of an xMAP-based 
Luminex assay in dried blood spots as a potential screening tool in FRDA. Both assays 
show strong potential as a screening tool for identifying carriers and FRDA patients in 
study populations, with the Luminex assay having slightly higher PPV and sensitivity in 
dried blood spots than the dipstick assay in whole blood. The assay used in clinical 
studies will depend on the context of the study, the clinical setting, and the tissues 
accessible to researchers. 
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We then applied the measurement of frataxin protein by lateral flow dipstick 
assay in a number of clinical settings. First, we demonstrated potential diagnostic 
capability of the assay in patients with unknown ataxias, including FRDA patients with 
atypical genetic composition. Seven of ten atypical patients had reduced frataxin protein 
levels measured in cheek swab samples. Subsequent MLPA analysis revealed a novel 
heterozygous partial exon 2/3 deletion in one patient, and a heterozygous exon 5 deletion 
in another; these findings expand the spectrum of known disease-causing mutations in 
FRDA. We also used the dipstick assay to monitor changes in frataxin protein in response 
to two pharmacological treatments: ex vivo HDAC inhibitor treatment in FRDA patient 
PBMCs, and in a FRDA patient receiving MAP combined chemotherapy for treatment of 
osteosarcoma. Our finding that frataxin levels appear to be unchanged over long periods 
of time suggest that detected changes in measured frataxin protein in response to 
treatment can largely be attributed to that treatment. Our last application of the dipstick 
assay involved determining whether polymorphisms in HDAC genes would predict 
frataxin protein levels. We found that a Ser46Asn SNP in SIRT6 predicted a less severe 
neurological phenotype and increased frataxin levels when accounting for age, sex, and 
GAA1 repeat length; however, changes in FRDA phenotype may not be strongly 
influenced by frataxin levels based on our linear regression model. We have shown in 
this thesis that the dipstick assay is useful in multiple clinical research settings where 
frataxin protein measurements can help answer questions related to diagnosis of atypical 
ataxia patients, response to pharmacological treatment, relationship to disease severity 
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and progression, and how levels respond to polymorphisms in genes regulating frataxin 
expression. 
Finally, we utilized stable isotope dilution using SILEC-labeled CoA internal 
standards and isotopic tracer analysis coupled with LC/MS to assess mitochondrial 
metabolism in FRDA samples. We measured a relative decrease in baseline acetyl-
CoA:succinyl-CoA ratios in frataxin knockdown HEK293 cells relative to scrambled 
siRNA controls. Similarly, we found an increase in succinyl-CoA in platelets isolated 
from FRDA patients compared to control platelets. However, these findings only 
represent a snapshot of mitochondrial metabolism, so we used isotopic tracer analysis to 
investigate changes in metabolic flux between FRDA and control cells. We found a 
significant decrease in [U-13C6]-glucose-derived [13C]-acetyl-CoA and a significant 
increase in [U-13C6]-glucose-derived [13C]-succinyl-CoA in HEK293 cells transfected 
with siRNA towards frataxin relative to scrambled siRNA controls. Interestingly, we 
found a significant increase in [U-13C16]-palmitic acid-derived [13C]-acetyl-CoA, 
suggesting increased fatty acid oxidation in frataxin-deficient cells. We then found that 
platelets isolated from controls and FRDA patients were metabolically active, and 
isotopomer analysis of short-chain acyl-CoAs could be assessed using isotopic labeling 
with [U-13C16]-palmitic acid in whole blood. We did not find significant labeling in 
platelets using [U-13C6]-glucose or [13C515N2]-glutamine, suggesting that platelets either 
do not rely on pathways involving these metabolites, or do not possess mechanisms to 
take up the isotopic tracers.93 We measured significant decreases in labeling of succinyl-
CoA in M2 (p = 0.01) and 3-HMG-CoA in M2 (p = 0.03) and M4 (p = 0.004) in FRDA 
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platelets relative to control by [U-13C16]-palmitic acid, suggesting patients may have 
impaired or less dependency on fatty acid metabolism relative to controls. Last, primary 
fibroblast lines from the Coriell Institute were used for better control over length of time 
cells were grown in the presence of heavy-labeled tracers. We found a significant amount 
of labeling of acetyl-CoA by [U-13C16]-palmitic acid and [U-13C6]-glucose after 72 hours. 
While we did not detect a significant difference in [U-13C6]-glucose-derived acetyl-CoA 
between control and FRDA fibroblasts, we did see a significant increase in [U-13C16]-
palmitic acid-derived acetyl-CoA in FRDA fibroblasts relative to controls, similar to 
transfected HEK293 cells. Taken together, we have shown a rearrangement in FRDA 
mitochondrial metabolism through the use of stable isotope dilution with SILEC internal 
standards and isotopic tracer analysis using [U-13C6]-glucose and [U-13C16]-palmitic acid. 
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5.2 Future Directions 
In this thesis, we have shown that both the dipstick assay and the Luminex 
xMAP-based assay are potentially useful as population screening and diagnostic tools 
with high PPV and a low rate of false negatives. These assays would be ideal for use in 
natural history studies to systematically follow frataxin levels over time alongside of 
other parameters of disease, or to measure frataxin levels in response to pharmacological 
intervention. While neurological exams and other performance-based measures are 
typically used to assess disease progression, they are not particularly sensitive to change, 
and are subject to intersite variability. Frataxin measurements represent a more 
standardized biochemical marker that shows relative stability over time in untreated 
individuals, and responds to pharmacological treatment aimed at increasing frataxin 
levels. While we have shown that frataxin levels may predict progression of disease as 
measured by a change in FARS scores, these calculations were based on retrospective 
data and operated under the assumption that frataxin levels were truly unchanging over 
time periods of up to eight years. If we include frataxin measurements as part of the 
routine clinical visit, we can utilize a more thorough and systematic approach to assess 
correlations between frataxin levels and disease severity and progression. These data 
could then be useful in helping to determine whether response to treatment correlates 
with rate of progression. 
In addition to use as a potential screening tool in general and clinical populations, 
we have shown that the dipstick assay has applications in clinical research settings aside 
from observing natural history and response to treatment. We have used dipstick assays 
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as a complementary diagnostic tool in FRDA patients with atypical genetic composition 
and uncovered novel heterozygous deletions in two patients, broadening the spectrum of 
known disease-causing mutations. Our next goal is to understand the effect these 
deletions and other point mutations may have on frataxin function, and what potential 
consequences may arise in the context for treatment. We have also uncovered elevated 
frataxin protein levels in select cell types of fractionated whole blood in a patient with a 
start codon mutation in the frataxin gene, underlying the importance of testing in multiple 
cell types for patients with suspected point mutations or deletions. We can confirm which 
cell types are responsible for the elevated frataxin levels through flow cytometry, and 
proceed to determine what about these mutations is responsible for the apparent 
upregulation of frataxin protein. Our last application of frataxin measurements involved 
determining the predictive value of SNPs in HDAC genes on frataxin expression and 
disease severity.  We found that a Ser46Asn polymorphism in SIRT6 predicts the severity 
of neurological FRDA phenotype when controlling for age, sex, and GAA1 repeat length, 
but no effects were noted on non neurological features of the disorder.  We also found 
that SIRT6 mutation status did not appear to predict frataxin levels, suggesting that the 
effect of these polymorphisms is mediated by an effect of SIRT6 itself on 
pathophysiological mechanisms downstream from frataxin deficiency. If such 
mechanisms can be identified, it suggests that SIRT6-mediated processes may have 
potential as molecular targets in FRDA. To date, we have only measured frataxin protein 
from whole blood in 181 of 505 genotyped patients in our database, resulting in small 
numbers of patients that carry the minor allele. We will collect blood samples for frataxin 
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measurements from as many of the remainder of these patients as we can to reducae 
variation, which may help to bring out more significant differences if any polymorphism 
does predict frataxin levels. In the meantime, we can use frataxin measurements in 
conjunction with other genes and mutations that may alter FRDA phenotype to determine 
whether a relationship exists between the two. Even if it becomes clear that these SNPs in 
SIRT genes modulate phenotype independent of frataxin, there may be mutations in other 
genes that affect phenotype through frataxin levels. For example, transcription factors 
including SRF and TFAP2 or the transcriptional coactivator PGC-1α may have mutations 
that alter regulation of frataxin expression.45,66,76,107,123,143,156 As with SIRT6, finding 
mutations in genes that predict frataxin level or disease severity will provide researchers 
with novel targets for therapeutic intervention in FRDA. 
While dipsticks have been developed to quantify up to four different proteins and 
enzymes including frataxin, the multiplex capability of the Luminex assay allows 
researchers to analyze hundreds of markers for multiple diseases or multiple biomarkers 
for the same disease in a single sample. This may particularly be useful as a newborn 
screening test, where one can test for FRDA and several other diseases using only a 
minimal amount of blood. By diagnosing FRDA at an earlier age, we potentially increase 
the chances of successfully managing the disease or slowing progression by intervening 
before significant cell death has occurred. While we have only measured frataxin levels 
using the Luminex assay in this thesis, we have the potential to analyze other markers of 
FRDA. For example, we have evidence that markers of cardiac damage, including 
cardiac troponin (CTnI) and galectin-3, are chronically elevated in FRDA patients 
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(Figure A.3), which may be associated with an increased risk for myocardial 
damage.52,220 However, we do not know how well these values are related to patient 
clinical features including frataxin levels, risk of developing cardiomyopathy, or 
progression of cardiomyopathy. With the Luminex assay, we could analyze both frataxin 
and CTnI from the same sample to potentially measure markers of both neurological and 
cardiac disease severity and progression. 
Finally, we have laid the foundation for analysis of mitochondrial metabolism in 
frataxin deficient cells relative to controls, including FRDA platelets and fibroblasts. The 
primary tissues affected in FRDA – heart, spinal cord, and pancreas – are clinically 
inaccessible, so we must rely on surrogate tissues to monitor their mitochondrial status. 
Even though platelets and fibroblasts are clinically unaffected in FRDA, they express 
reduced levels of frataxin protein and may display subclinical alterations in mitochondrial 
metabolism that may provide us with some insight as to why certain frataxin-deficient 
cell types are more susceptible to cell death than others in FRDA. In the future, we can 
use tissues from mouse models of FRDA or iPS cells to more accurately model pathology 
seen in affected tissues.108,124 While we have uncovered differences in mitochondrial 
metabolism in FRDA through the use of stable isotope dilution and isotopic tracer 
analysis, this methodology can be extended to analyze metabolism in a variety of other 
disorders with known mitochondrial dysfunction. We can use SILEC internal standards 
or isotopic tracer analysis to measure ratios of metabolites positioned upstream and 
downstream of any enzyme of interest to determine relative enzyme activities amongst 
the samples. This is potentially useful not only in the context of ISC-containing enzymes 
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in FRDA, but for enzymes at the root of other mitochondrial disorders, as well. For 
example, by measuring ratios of propionyl-CoA and methylmalonyl-CoA derived from 
[13C]-labeled substrates, we could reveal a possible deficiency in propionyl-CoA 
decarboxylase. Similarly, medium-chain acyl-CoA dehydrogenase deficiency could be 
detected through the use of [13C]-labeled substrates in fatty acid oxidation. In the 
meantime, we can correct some of the issues we had surrounding extraction and analysis 
of long-chain acyl-CoA species for a more thorough analysis of fatty acid oxidation, and 
begin to incorporate the use of more isotopic tracers for analysis. Although we did have 
some difficulty with [U-13C6]-glucose and [13C515N2]-glutamine labeling in platelets, this 
may have been a result of platelets lacking the relevant uptake mechanisms; however, 
platelets do express glutamate transporters and glutamine synthetase, so we hope to use 
[13C515N]-glutamic acid as another tracer to further assess metabolism downstream of 
aconitase in the TCA cycle.21,160,222 We can also use [13C6]-leucine, [13C6]-isoleucine, or 
[13C5]-valine as tracers to assess metabolism through the TCA cycle from branched chain 
amino acid metabolism, and analyze heavy-labeled organic acids in addition to CoA 
species to have a more complete characterization of metabolic flux through and around 
the TCA cycle. Ideally, as we troubleshoot the nuances associated with various isotopic 
tracers, we will theoretically be able to perform isotopomer analysis using a variety of 
labeled compounds to analyze mitochondrial metabolism from a single blood sample in a 
relatively inexpensive and efficient manner for biomarker analysis of multiple metabolic 
disorders. Ultimately, novel biomarkers will provide researchers with further insight into 
mechanisms of disease pathology and development of potential new treatments.
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Appendix 
 
Figure A.1 – Dipstick assay standard curve using recombinant frataxin protein in 
triplicate. (A) The assay was tested with up to 2000 pg of recombinant frataxin, and (B) 
the assay remained linear through 500 pg. Error bars represent standard deviations (n=3). 
mABS: milliabsorbance. 
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Figure A.2 – Dipstick assay standard curves using samples collected from a 
representative control in triplicate. (A) Platelets, (B) Whole Blood, and (C) Buccal Cells 
all remained within the linear range of the assay over a large range of extractable protein 
concentrations. Error bars represent standard deviations (n=3). mABS: milliabsorbance. 
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Table A.1 – Clinical features of FRDA patients providing whole blood samples for 
frataxin measurement by dipstick assay.  
 
 
Table A.2 – ROC analysis data comparing two screening methods from frataxin 
measurements in whole blood samples by dipstick assay. CTL: control, CR: carrier.
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Table A.3 – Clinical features of FRDA patients providing cheek swab samples for 
frataxin measurement by dipstick assay.  
 
 
Table A.4 - ROC analysis data comparing two screening methods from frataxin 
measurements in cheek swab samples by dipstick assay. CTL: control, CR: carrier.
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Table A.5 – Spike and recovery analysis in representative control buccal cell and whole 
blood samples run in triplicate. The assay demonstrated sufficient recovery of up to 100 
pg of recombinant frataxin in both cell types without significant enhancement or 
interference from the test sample milieu. RF: recombinant frataxin, BC: buccal cell 
sample, mABS: milliabsorbance. 
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Table A.6 – Lateral flow immunoassay intra- and inter-assay variation and inter-sample 
variation in whole blood and cheek swab samples run in triplicate.  Samples from a 
representative control were collected on three different days and frataxin levels were 
measured in triplicate. Intra-assay variation: variation between samples from the same 
day on the same plate, Inter-assay variation: variation between plates from the same 
sample, Inter-sample variation: variation between samples from the same plate, mABS: 
milliabsorbance, CV: coefficient of variation, CTL: control sample. 
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Table A.7 – Whole blood and cheek swap sample storage data. Mean corrected frataxin 
mABS values from a current representative control were compared to samples stored at -
80°C collected from the previous four years (when applicable). All samples were run in 
triplicate and maintained low intra-assay CV values, but cheek swab samples showed 
more variation between samples from year-to-year compared to whole blood. CV: 
coefficient of variation, mABS: milliabsorbance.
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Table A.8 - Clinical features of FRDA patients providing whole blood samples for 
comparisons in frataxin measurements by dipstick assay and Luminex assay. 
 
Table A.9 - ROC analysis data comparing population screening utility in whole blood by 
dipstick assay versus Luminex assay. CTL: control, CR: carrier.
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Table A.10 – Clinical information and frataxin measurements by dipstick assay in buccal 
cells and whole blood from FRDA patients with point mutations. BC: buccal cell sample. 
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Table A.11 – Longitudinal frataxin measurements in whole blood from a representative 
FRDA patient run in triplicate (GAA1 = 454, GAA2 = 777, age of onset = 15) reveal the 
mean corrected mABS values for frataxin protein measurements remain relatively 
constant over time. The p-values represent results of paired t-test analyses on samples 
from consecutive dates. CV: coefficient of variation, mABS: milliabsorbance. 
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Table A.12 - Clinical information and frataxin measurements by dipstick assay and 
Western blot in fibroblasts from the Coriell Institute.
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Table A.13 – Clinical information and frataxin measurements by dipstick assay in 
platelets isolated from FRDA patients in the mitochondrial metabolism study.
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Figure A.3 – Galectin-3 measurements in plasma as a marker of myocardial damage from 
controls, carriers, FRDA patients, and acute heart failure patients. FRDA patients have 
slightly elevated galectin-3 levels compared to controls and carriers, but the increase is 
not statistically significant. CHF: coronary heart failure patients.
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